0001847345 2026-01-01 2026-06-30 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-01-01 2026-06-30 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-01-01 2026-06-30 0001847345 2026-08-07 0001847345 2026-06-30 0001847345 2025-12-31 0001847345 us-gaap:RelatedPartyMember 2026-06-30 0001847345 us-gaap:RelatedPartyMember 2025-12-31 0001847345 ASBP:SeriesAConvertiblePreferredStockMember 2026-06-30 0001847345 ASBP:SeriesAConvertiblePreferredStockMember 2025-12-31 0001847345 2026-01-16 2026-01-16 0001847345 2026-05-11 2026-05-11 0001847345 2026-04-01 2026-06-30 0001847345 2025-04-01 2025-06-30 0001847345 2025-01-01 2025-06-30 0001847345 us-gaap:CommonStockMember 2025-12-31 0001847345 us-gaap:PreferredStockMember 2025-12-31 0001847345 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001847345 us-gaap:RetainedEarningsMember 2025-12-31 0001847345 us-gaap:CommonStockMember 2026-03-31 0001847345 us-gaap:PreferredStockMember 2026-03-31 0001847345 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001847345 us-gaap:RetainedEarningsMember 2026-03-31 0001847345 2026-03-31 0001847345 us-gaap:CommonStockMember 2024-12-31 0001847345 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001847345 us-gaap:RetainedEarningsMember 2024-12-31 0001847345 2024-12-31 0001847345 us-gaap:CommonStockMember 2025-03-31 0001847345 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001847345 us-gaap:RetainedEarningsMember 2025-03-31 0001847345 2025-03-31 0001847345 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001847345 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001847345 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001847345 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001847345 2026-01-01 2026-03-31 0001847345 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001847345 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001847345 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001847345 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001847345 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001847345 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001847345 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001847345 2025-01-01 2025-03-31 0001847345 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001847345 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001847345 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001847345 us-gaap:CommonStockMember 2026-06-30 0001847345 us-gaap:PreferredStockMember 2026-06-30 0001847345 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001847345 us-gaap:RetainedEarningsMember 2026-06-30 0001847345 us-gaap:CommonStockMember 2025-06-30 0001847345 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001847345 us-gaap:RetainedEarningsMember 2025-06-30 0001847345 2025-06-30 0001847345 2025-02-28 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-02-01 2025-02-28 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-02-28 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2026-02-01 2026-02-28 0001847345 srt:MaximumMember us-gaap:CommonStockMember ASBP:PurchaseAgreementMember 2025-11-01 2025-11-30 0001847345 us-gaap:CommonStockMember ASBP:PurchaseAgreementMember 2026-04-01 2026-04-30 0001847345 country:US 2026-04-01 2026-06-30 0001847345 country:US 2026-01-01 2026-06-30 0001847345 country:CA 2026-04-01 2026-06-30 0001847345 country:CA 2026-01-01 2026-06-30 0001847345 ASBP:InternationalMember 2026-04-01 2026-06-30 0001847345 ASBP:InternationalMember 2026-01-01 2026-06-30 0001847345 2025-01-01 2025-12-31 0001847345 us-gaap:IPOMember 2026-06-30 0001847345 us-gaap:PrivatePlacementMember 2026-06-30 0001847345 2025-02-17 2025-02-17 0001847345 ASBP:CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember us-gaap:ParentMember 2025-02-17 2025-02-17 0001847345 ASBP:CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember ASBP:ConversionRatioMember 2025-02-17 2025-02-17 0001847345 ASBP:CommonStockObligationSharesIssuedMember srt:ParentCompanyMember 2025-02-17 2025-02-17 0001847345 ASBP:CommonStockObligationSharesIssuedMember ASBP:ConversionRatioMember 2025-02-17 2025-02-17 0001847345 us-gaap:ParentMember 2025-02-17 2025-02-17 0001847345 ASBP:ConversionRatioMember 2025-02-17 2025-02-17 0001847345 ASBP:SponsorAndSsvkAssociatesLlcMember ASBP:LoanAndTransferAgreementMember 2025-02-17 0001847345 ASBP:SponsorAndSsvkAssociatesLlcMember ASBP:LoanAndTransferAgreementMember 2026-06-30 0001847345 ASBP:SponsorAndSsvkAssociatesLlcMember ASBP:LoanAndTransferAgreementMember 2025-12-31 0001847345 ASBP:ApogeePharmaMember ASBP:LoanAndTransferAgreementMember 2025-02-17 0001847345 ASBP:ApogeePharmaMember ASBP:LoanAndTransferAgreementMember 2026-06-30 0001847345 ASBP:ApogeePharmaMember ASBP:LoanAndTransferAgreementMember 2025-12-31 0001847345 ASBP:JinalShethMember ASBP:LoanAndTransferAgreementMember 2025-02-17 0001847345 ASBP:JinalShethMember ASBP:LoanAndTransferAgreementMember 2026-06-30 0001847345 ASBP:JinalShethMember ASBP:LoanAndTransferAgreementMember 2025-12-31 0001847345 ASBP:ApogeePharmaTwoMember ASBP:SecondLoanAndTransferAgreementtMember 2025-02-17 0001847345 ASBP:ApogeePharmaTwoMember ASBP:SecondLoanAndTransferAgreementtMember 2026-06-30 0001847345 ASBP:ApogeePharmaTwoMember ASBP:SecondLoanAndTransferAgreementtMember 2025-12-31 0001847345 ASBP:JinalShethMember ASBP:LoanAndTransferAgreementMember 2026-04-14 0001847345 ASBP:JinalShethMember ASBP:LoanAndTransferAgreementMember 2026-04-15 0001847345 ASBP:FirstSubscriptionAgreementMember 2024-03-05 2024-03-05 0001847345 ASBP:SecondSubscriptionAgreementsMember 2024-05-09 2024-05-09 0001847345 ASBP:FirstSubscriptionAgreementMember 2025-02-17 0001847345 ASBP:FirstAndSecondSubscriptionAgreementMember 2026-04-01 2026-06-30 0001847345 ASBP:FirstAndSecondSubscriptionAgreementMember 2026-01-01 2026-06-30 0001847345 ASBP:FirstAndSecondSubscriptionAgreementMember 2026-01-01 2026-01-31 0001847345 ASBP:FirstAndSecondSubscriptionAgreementMember 2026-06-30 0001847345 ASBP:FirstAndSecondSubscriptionAgreementMember 2025-12-31 0001847345 ASBP:ModifiedPromissoryNoteFeeAgreementMember 2024-10-02 0001847345 2026-04-30 2026-04-30 0001847345 2026-06-29 2026-06-29 0001847345 ASBP:SponsorMember 2025-02-17 2025-02-17 0001847345 ASBP:AffiliatesMember 2026-06-30 0001847345 ASBP:AffiliatesMember 2025-12-31 0001847345 2024-09-27 2024-09-27 0001847345 2024-09-27 0001847345 ASBP:SeptemberTwentySevenTwoThousandTwentyFourMember 2026-01-01 2026-06-30 0001847345 ASBP:SeptemberTwentySevenTwoThousandTwentyFourMember 2026-04-01 2026-06-30 0001847345 ASBP:SeptemberTwentySevenTwoThousandTwentyFourMember 2025-04-01 2025-06-30 0001847345 ASBP:SeptemberTwentySevenTwoThousandTwentyFourMember 2025-01-01 2025-06-30 0001847345 2024-12-31 2024-12-31 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember 2026-01-01 2026-03-31 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember 2026-04-01 2026-06-30 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember 2025-04-01 2025-06-30 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember 2026-01-01 2026-06-30 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember 2025-01-01 2025-06-30 0001847345 ASBP:SeptemberTwentySevenTwoThousandTwentyFourMember us-gaap:RelatedPartyMember 2026-06-30 0001847345 ASBP:SeptemberTwentySevenTwoThousandTwentyFourMember us-gaap:RelatedPartyMember 2025-12-31 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember us-gaap:RelatedPartyMember 2026-06-30 0001847345 ASBP:DecemberThirtyFirstTwoThousandTwentyFourMember us-gaap:RelatedPartyMember 2025-12-31 0001847345 ASBP:SecuritiesPurchaseAgreementMember ASBP:CobraAlternativeCapitalStrategiesLLCMember 2025-02-17 0001847345 ASBP:SecuritiesPurchaseAgreementMember ASBP:CobraAlternativeCapitalStrategiesLLCMember 2025-02-17 2025-02-17 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-08-01 2025-08-31 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-09-01 2025-09-30 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2026-04-01 2026-06-30 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2026-01-01 2026-06-30 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-04-01 2025-06-30 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-01-01 2025-06-30 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2026-01-01 2026-01-31 0001847345 ASBP:SeriesAConvertiblePreferredStockMember ASBP:SecuritiesPurchaseAgreementMember 2026-01-01 2026-01-31 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2026-06-30 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2025-12-31 0001847345 ASBP:AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-08-19 0001847345 ASBP:AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-08-19 2025-08-19 0001847345 ASBP:AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-08-18 0001847345 ASBP:AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember 2025-08-19 0001847345 ASBP:FirstTrancheMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-08-19 0001847345 ASBP:SecondTrancheMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-09-22 0001847345 ASBP:ThirdTrancheMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-09-30 0001847345 ASBP:AugustTwentyTwentyFiveNotesMember ASBP:AugustSecuritiesPurchaseAgreementMember 2025-01-01 2025-12-31 0001847345 us-gaap:CommonStockMember 2026-01-01 2026-01-31 0001847345 ASBP:DebenturesMember ASBP:SecuritiesPurchaseAgreementMember 2026-01-26 0001847345 ASBP:DebenturesMember ASBP:SecuritiesPurchaseAgreementMember 2026-01-26 2026-01-26 0001847345 ASBP:DebenturesMember ASBP:SecuritiesPurchaseAgreementMember 2026-04-01 2026-06-30 0001847345 ASBP:DebenturesMember ASBP:SecuritiesPurchaseAgreementMember 2026-01-01 2026-06-30 0001847345 us-gaap:WarrantMember 2025-05-13 0001847345 ASBP:PrivatePlacementWarrantsMember 2025-05-13 0001847345 ASBP:SecondELOCAgreementMember ASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember 2025-11-11 2025-11-11 0001847345 ASBP:SecondELOCAgreementMember ASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember 2025-11-11 2025-12-31 0001847345 ASBP:SecondELOCAgreementMember ASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember 2026-01-01 2026-01-31 0001847345 ASBP:SecondELOCAgreementMember ASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember 2026-04-01 2026-06-30 0001847345 ASBP:SecondELOCAgreementMember ASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember 2026-01-01 2026-06-30 0001847345 ASBP:SecondELOCAgreementMember 2026-06-30 0001847345 ASBP:SecondELOCAgreementMember 2025-12-31 0001847345 ASBP:InstaprinPharmaceuticalsIncMember 2022-03-28 0001847345 ASBP:ChiefExecutiveMember ASBP:InstaprinPharmaceuticalsIncMember 2022-03-28 0001847345 ASBP:PurchaseAgreementMember 2026-06-10 2026-06-10 0001847345 ASBP:AspireCreditFacilityMember 2026-05-01 2026-05-31 0001847345 ASBP:DriverControlsSystemsBusinessUnitMember ASBP:AspireCreditFacilityMember 2026-05-31 0001847345 us-gaap:SeriesAPreferredStockMember ASBP:SecuritiesPurchaseAgreementMember 2026-02-06 2026-02-06 0001847345 us-gaap:SeriesAPreferredStockMember ASBP:SecuritiesPurchaseAgreementMember 2026-02-06 0001847345 ASBP:SecuritiesPurchaseAgreementMember 2026-02-06 0001847345 us-gaap:SeriesAPreferredStockMember ASBP:SecuritiesPurchaseAgreementMember 2026-04-15 2026-04-15 0001847345 ASBP:SeriesAConvertiblePreferredStockMember 2026-02-02 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-02-02 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-02-02 2026-02-02 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-02-06 2026-02-06 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-04-13 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-04-13 2026-04-13 0001847345 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001847345 us-gaap:SeriesAPreferredStockMember 2026-02-02 2026-02-02 0001847345 ASBP:PublicWarrantsMember us-gaap:CommonClassAMember 2026-06-30 0001847345 ASBP:PrivatePlacementWarrantsMember us-gaap:CommonClassAMember 2026-06-30 0001847345 ASBP:PublicWarrantsMember 2026-06-30 0001847345 ASBP:PrivatePlacementWarrantsMember 2026-06-30 0001847345 ASBP:PublicWarrantsMember 2025-12-31 0001847345 ASBP:PrivatePlacementWarrantsMember 2025-12-31 0001847345 ASBP:PublicWarrantsMember 2026-01-01 2026-06-30 0001847345 ASBP:CorporateAdvisoryAgreementMember 2024-02-29 2024-02-29 0001847345 ASBP:CorporateAdvisoryAgreementMember 2025-01-03 2025-01-03 0001847345 ASBP:CorporateAdvisoryAgreementMember 2025-02-01 2025-02-28 0001847345 ASBP:CorporateAdvisoryAgreementMember 2026-04-01 2026-06-30 0001847345 ASBP:CorporateAdvisoryAgreementMember 2026-01-01 2026-06-30 0001847345 ASBP:CorporateAdvisoryAgreementMember 2025-04-01 2025-06-30 0001847345 ASBP:CorporateAdvisoryAgreementMember 2025-01-01 2025-06-30 0001847345 ASBP:AspireBiopharmaWarrantsMember 2024-12-31 0001847345 ASBP:AspireBiopharmaWarrantsMember 2025-01-21 0001847345 ASBP:AspireBiopharmaWarrantsMember 2025-01-21 2025-01-21 0001847345 ASBP:AspireBiopharmaWarrantsMember 2026-01-16 2026-01-16 0001847345 ASBP:SettlementAgreementMember 2025-04-28 2025-04-28 0001847345 ASBP:ConvertibleNotesMember 2025-01-01 2025-12-31 0001847345 ASBP:ConvertibleNotesMember us-gaap:CommonStockMember 2026-01-01 2026-01-31 0001847345 ASBP:ArenaBusinessSolutionsGlobalSPCIILtdMember 2026-01-01 2026-01-31 0001847345 us-gaap:InvestorMember us-gaap:CommonStockMember ASBP:SharePurchaseAgreementMember 2026-01-01 2026-01-31 0001847345 us-gaap:InvestorMember us-gaap:CommonStockMember ASBP:SharePurchaseAgreementMember 2026-04-07 2026-04-07 0001847345 ASBP:ExchangeAgreementsMember 2026-01-01 2026-01-01 0001847345 ASBP:ExchangeAgreementsMember 2026-01-01 2026-01-31 0001847345 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001847345 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001847345 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001847345 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001847345 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001847345 us-gaap:MeasurementInputSharePriceMember us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001847345 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleNotesPayableMember 2025-12-31 0001847345 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001847345 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-06-30 0001847345 us-gaap:FairValueInputsLevel3Member 2026-06-30 0001847345 us-gaap:MeasurementInputSharePriceMember 2026-06-30 0001847345 us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001847345 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001847345 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001847345 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001847345 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001847345 srt:MinimumMember ASBP:MeasurementInputLikelihoodMember 2026-06-30 0001847345 srt:MaximumMember ASBP:MeasurementInputLikelihoodMember 2026-06-30 0001847345 srt:MinimumMember ASBP:MeasurementInputLikelihoodMember 2025-12-31 0001847345 srt:MaximumMember ASBP:MeasurementInputLikelihoodMember 2025-12-31 0001847345 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001847345 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001847345 us-gaap:FairValueInputsLevel3Member 2026-04-01 2026-06-30 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2025-12-31 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-01-01 2026-03-31 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-03-31 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-04-01 2026-06-30 0001847345 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-06-30 0001847345 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001847345 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001847345 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001847345 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001847345 ASBP:SeriesAConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-07-31 0001847345 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-07-31 0001847345 ASBP:PurchaseAgreementMember 2026-06-10 0001847345 us-gaap:SubsequentEventMember ASBP:NotePurchaseAgreementMember 2026-07-31 0001847345 us-gaap:SubsequentEventMember ASBP:NotePurchaseAgreementMember 2026-07-31 2026-07-31 0001847345 us-gaap:SubsequentEventMember ASBP:ManagementServicesAgreementMember 2026-08-06 2026-08-06 iso4217:USD shares iso4217:USD shares pure ASBP:Integer false Q2 --12-31 0001847345 10-Q true 2026-06-30 2026 false 001-41293 ASPIRE BIOPHARMA HOLDINGS, INC. DE 33-3467744 23150 Fashion Drive Suite 232 Estero FL 33928 (908) 987-3002 Common Stock, par value $0.0001 per share ASBP NASDAQ Warrants, each exercisable for one share of common stock ASBPW NASDAQ Yes Yes Non-accelerated Filer true true false false 1402557 12167136 1003904 1009958 55102 288450 253160 13465544 1312166 75000 13540544 1312166 972108 1014377 714088 1008569 353679 885564 1000000 40954 499214 1500000 1290476 1686196 7592833 96527 95662 1782723 7688495 0.0001 0.0001 10000000 10000000 0 0 0 0 30000 0 30000 0 0.0001 0.0001 17050 17050 0 0 2 0.0001 0.0001 490000000 490000000 1295234 1295234 117780 117780 129 12 43506805 20881740 -31749115 -27258081 11757821 -6376329 13540544 1312166 1 for 40 reverse stock split 1 for 30 reverse stock split 63104 91457 50818 73421 42372 42372 -30086 -24336 157500 0 157500 14131250 970211 395692 1990668 15469240 233482 352887 530205 615980 1215025 51311 1549764 271150 229418 229418 2648136 799890 4300055 16356370 -2678222 -799890 -4324391 -16356370 56676 61685 527893 1595315 817824 -275 -289401 251532 -384318 1353679 -364109 1115455 -364109 1410080 -1181403 -166643 -1566251 -1268142 -1981293 -4491034 -17922621 -1268142 -1981293 -4491034 -17922621 1037874 1037874 41111 41111 599714 599714 36410 36410 -1.22 -1.22 -48.19 -48.19 -7.49 -7.49 -492.24 -492.24 1 for 40 reverse stock split 1 for 30 reverse stock split 117780 12 20881740 -27258081 -6376329 12776 1 8951118 8951119 974 943801 943801 1625 163817 163817 26333 3 1390397 1390400 207 13406 13406 21525 2 2005139 2005141 -3222892 -3222892 167470 17 13750 1 34349418 -30480973 3868463 12500 1 8999999 9000000 1122764 112 -9200 -112 5000 157500 157500 -1268142 -1268142 1295234 129 17050 2 43506805 -31749115 11757821 1 for 40 reverse stock split 1 for 30 reverse stock split 23001 2 1237143 -2777233 -1540088 4780 1 -1 6048 1 -4602577 -4602576 4614 1 -1 922 -1 1 1385 14131250 14131250 -15941328 -15941328 40750 4 10765815 -18718561 -7952742 40750 4 10765815 -18718561 -7952742 521 317250 317250 -1981293 -1981293 41271 4 11083065 -20699854 -9616785 41271 4 11083065 -20699854 -9616785 1 for 40 reverse stock split 1 for 30 reverse stock split -4491034 -17922621 1583890 817824 1115455 -364109 251532 -384318 9008 42372 157500 14131250 954856 553833 77662 -11946 1041420 -44481 -15359 1027920 -111026 -5154196 -2891838 17951119 265828 3000000 75000 2000000 2173913 50000 1384778 221390 16317428 3094438 11163232 202600 1003904 3633 12167136 206233 163817 1390400 2005141 943801 112 13406 353679 1577057 1000000 1000000 1828098 499214 49034 157500 14448500 <p id="xdx_80D_eus-gaap--NatureOfOperations_znsncP3e5zQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_82A_zOJ6Z0xsEFKe">Description of Organization and Business</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Organization and Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aspire Biopharma Holdings, Inc. (the “Company” or “Aspire”) was incorporated as PowerUp Acquisition Corp., a Cayman Islands exempted company, on February 9, 2021, then domesticated to Delaware as a corporation on February 17, 2025. On February 17, 2025, the Company completed the reverse recapitalization transaction (“Reverse Recapitalization”) (<i>see Note 3. Reverse Recapitalization</i>) and changed its name to Aspire Biopharma Holdings, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aspire is an early-stage biopharmaceutical company which engages in the business of developing and marketing disruptive technology for novel sublingual delivery mechanisms initially for known drugs and supplements, such as aspirin and caffeine products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has two wholly-owned subsidiaries, Aspire Biopharma Inc., a Delaware corporation, formed on October 8, 2021, and Buzz Bomb Caffeine Co. LC, a Utah LLC, formed on May 5, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse Recapitalization</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2024, the Company (then known as PowerUp Acquisition Corp.) entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with PowerUp Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), Srirama Associates, LLC, a Delaware limited liability company (the “New Sponsor”), Stephen Quesenberry, in the capacity as the seller representative, and Aspire Biopharma, Inc., a Puerto Rico corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025 (the “Closing Date”), the Company consummated the reverse recapitalization transaction (the “Reverse Recapitalization”) in accordance with the terms of the Merger Agreement. In connection with the consummation of the Reverse Recapitalization, the Company changed its name from PowerUp Acquisition Corp. to “Aspire Biopharma Holdings, Inc.” (<i>see Note 3. Reverse Recapitalization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse Stock Split</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 16, 2026, the Company effected a 1-for-40 reverse stock split with respect to its common stock (the “Reverse Split”). All share and per share information in these unaudited condensed consolidated financial statements gives effect to this reverse stock split, including restating prior period amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2026, the Company effected a 1-for-30 reverse stock split with respect to its common stock (the “Second Reverse Split”) (collectively with the Reverse Split, the “Reverse Splits”). All share and per share information in these unaudited condensed consolidated financial statements gives effect to the Reverse Splits, including restating prior-period amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Reverse Splits had no effect on the Company’s authorized number of shares of common stock, the par value of common stock, the public warrants outstanding, total assets, total liabilities, or stockholders’ equity (deficit). The Company restated the common stock outstanding (shares and amount) and additional paid-in capital to reflect the number of shares outstanding after the Reverse Splits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Management’s Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary sources of liquidity have been cash from financing activities. As of June 30, 2026, working capital was $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_c20260630_zaEZzU9nsxr" title="Working capital">11,779,348</span> and cash and cash equivalents was $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20260630_zsHSJUqsI61i" title="cash and cash equivalents">12,167,136</span>. For the six months ended June 30, 2026, net loss was $<span id="xdx_90B_eus-gaap--NetIncomeLoss_iN_di_c20260101__20260630_zgWm6wvZCna2" title="Net loss">4,491,034</span> and accumulated deficit totaled $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20260630_zhWCmoEATBIb" title="Accumulated deficit">31,749,115</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2025, the Company received proceeds of approximately $<span id="xdx_907_ecustom--NetCashReceivedInBusinessCombination_iI_c20250228_zaFfmYInwUH4" title="Business combination proceeds">265,827</span> as a result of the Reverse Recapitalization. Immediately after the consummation of the Reverse Recapitalization, the Company received $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zG3zPKIP1SSi" title="Proceeds from issuance of common stock">3,000,000</span> from the issuance of convertible notes and an additional net proceeds of $<span id="xdx_905_ecustom--ProceedsFromIssuanceOfConvertibleSecurities_iI_c20250228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvz4B6evsCP8" title="Business combination additional amount">2,661,459</span> after partial repayment of the convertible notes and deal costs pursuant to the August 19, 2025 Securities Purchase Agreement. In February 2026, the Company entered into a Securities Purchase Agreement (<i>see Note 7. Securities Purchase Agreement</i>) to which it received a net payout of approximately $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20260201__20260228__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNqvmHxs5C9c" title="Received net payout">6,777,206</span> after repayment of the remaining convertible notes and deal costs under the first tranche for purchases of convertible preferred stock. The Company also entered into an ELOC agreement in November 2025, pursuant to which it can sell up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20251101__20251130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zMnEwEc2p6wg" title="Number of common stock">100</span> million in common stock over 24 months. In April 2026, the Company closed the final tranche of the Securities Purchase Agreement and received an additional $<span id="xdx_90E_ecustom--PaymentsForApplicableFee_c20260401__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z5cOhyBNgZKh" title="Payments for applicable fee">9,000,000</span> after payment of applicable fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has determined that the Company’s current liquidity position is sufficient to fund its operations for at least one year after the filing of these unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 11779348 12167136 -4491034 -31749115 265827 3000000 2661459 6777206 100000000 9000000 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zkDFuXybqhYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. <span id="xdx_821_zvkRkROYjdd3">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please see Note 2. <i>Summary of Significant Accounting Policies </i>to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (“2025 Annual Report on Form 10-K”), filed with the SEC on March 30, 2026, as amended on Form 10-K/A filed with the SEC on April 8, 2026, for a description of all significant accounting policies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWCM5a5iS0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zOYyjXXKyAG6">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of June 30, 2026, and December 31, 2025, and for the three and six months ended June 30, 2026, and 2025. The Company’s condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and therefore do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2025, which are included in the 2025 Annual Report on Form 10-K, as amended on Form 10-K/A.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interim condensed consolidated financial statements are unaudited, and in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of results for the periods presented. The results of operations for the three and six months ended June 30, 2026, are not necessarily indicative of the results to be expected for the full year due primarily to the impact of the continued uncertainty of general economic conditions that may impact the Company’s markets for the remainder of fiscal year 2026. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znLcS1IFdRW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zo74kGUtFzd2">Cash, Cash Equivalents and Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of short-term, highly liquid investments with an original maturity of three months or less from the date of acquisition. Certain of the Company’s cash and cash equivalents balances exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what it believes to be credit-worthy financial institutions. At June 30, 2026, and December 31, 2025, cash equivalents were $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20260630_zVeFnmAnRe1b" title="Cash equivalents">11,652,779</span> and $<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20251231_zwPaQyPu3yOh">0</span>, respectively. As of June 30, 2026, and December 31, 2025, the Company had $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20260630_zUG5xYX8hERg" title="FDIC limit">11,320,840</span> and $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z7KdK856Hp66" title="FDIC limit">550,130</span>, respectively, in deposits in U.S banks in excess of the FDIC limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z3JEDjpOLg9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zQ8nfENQHlr7">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zkjCuLWFsuNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table details total revenues by major geographic area for the periods presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z3B16izuVpz3" style="display: none">Schedule of Total Revenues by Major Geographical Area</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260401__20260630_zpu6HCvcfEY5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260630_zHjUJKmnymN1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__country--US_z16uJZ3Nyb49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,028</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">85,171</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__country--CA_zK1fIbUeFGjl" style="vertical-align: bottom; background-color: White"> <td>Canada</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">864</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__custom--InternationalMember_zaxUHQwQOVc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International<sup id="xdx_F46_zk6oJNGhxW06">(1)</sup></span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,692</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,422</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_zPlA0WRBQa3i" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,457</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F06_ztxyTbwGLl0j">(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F17_z6qoczFUDlLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International revenues are defined as revenues generated from sales to customers outside of the U. S. and Canada.</span></td> </tr></table> <p id="xdx_8AC_z4ytyo7jp2Id" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One customer accounted for approximately 15% of the Company’s total revenues during the six months ended June 30, 2026. Revenue from this customer primarily related to a one-time sale and is not expected to represent a recurring source of revenue. No other customer accounted for 10% or more of the Company’s total revenues during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z5pxUajfwPV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_z26q4GoIzKT5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventories</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consisting of finished goods are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete, spoiled, or in excess of future demand. The Company records an impairment that is charged directly to cost of revenue when it determines the product is obsolete, spoiled or in excess of future demand, and the Company will not be able to sell it at a normal profit above it carrying value. During the three months ended June 30, 2026, the Company determined that $<span id="xdx_90A_eus-gaap--InventoryWriteDown_c20260401__20260630_zZmHinvUCa23" title="Impaired due to obsolesce">42,372</span> was impaired due to obsolesce and recorded the impairment to inventory write-off included in cost of revenue in the accompanying unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbhxsIyR7Skd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zyonkRAUs5N8">Recently Issued Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2024-03<i>, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-04) — Disaggregation of Income Statement Expenses (“ASU 2024-03”)</i>, and in January 2025, the FASB issued ASU 2025-01 — <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date </i>(“ASU 2025-01”). ASU 2024-03 requires additional disclosure of the nature of expenses included in the statement of operations as well as disclosures about specific types of expenses included in the expense captions presented in the statement of operations. ASU 2024-03, as clarified by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. Both early adoption and retrospective application are permitted. The Company is currently assessing the impact of this ASU; however expects to enhance expense disclosures based on the new requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2025, the FASB issued ASU 2025-11 <i>– Interim Reporting (Topic 270): Narrow-Scope Improvements</i> (“ASU 2025-11”). ASU 2025-11 clarifies the interim reporting guidance in the Accounting Standards Codification (“ASC”), adding a comprehensive list of required interim disclosures and a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim periods within annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating these new disclosure requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other ASUs issued and not yet effective as of June 30, 2026, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current or future financial position or results of operations.</span></p> <p id="xdx_851_zsL0hrpvehs9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWCM5a5iS0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zOYyjXXKyAG6">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of June 30, 2026, and December 31, 2025, and for the three and six months ended June 30, 2026, and 2025. The Company’s condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and therefore do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2025, which are included in the 2025 Annual Report on Form 10-K, as amended on Form 10-K/A.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interim condensed consolidated financial statements are unaudited, and in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments necessary for a fair presentation of results for the periods presented. The results of operations for the three and six months ended June 30, 2026, are not necessarily indicative of the results to be expected for the full year due primarily to the impact of the continued uncertainty of general economic conditions that may impact the Company’s markets for the remainder of fiscal year 2026. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znLcS1IFdRW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zo74kGUtFzd2">Cash, Cash Equivalents and Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of short-term, highly liquid investments with an original maturity of three months or less from the date of acquisition. Certain of the Company’s cash and cash equivalents balances exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what it believes to be credit-worthy financial institutions. At June 30, 2026, and December 31, 2025, cash equivalents were $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20260630_zVeFnmAnRe1b" title="Cash equivalents">11,652,779</span> and $<span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20251231_zwPaQyPu3yOh">0</span>, respectively. As of June 30, 2026, and December 31, 2025, the Company had $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20260630_zUG5xYX8hERg" title="FDIC limit">11,320,840</span> and $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z7KdK856Hp66" title="FDIC limit">550,130</span>, respectively, in deposits in U.S banks in excess of the FDIC limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 11652779 0 11320840 550130 <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z3JEDjpOLg9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zQ8nfENQHlr7">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zkjCuLWFsuNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table details total revenues by major geographic area for the periods presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z3B16izuVpz3" style="display: none">Schedule of Total Revenues by Major Geographical Area</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260401__20260630_zpu6HCvcfEY5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260630_zHjUJKmnymN1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__country--US_z16uJZ3Nyb49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,028</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">85,171</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__country--CA_zK1fIbUeFGjl" style="vertical-align: bottom; background-color: White"> <td>Canada</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">864</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__custom--InternationalMember_zaxUHQwQOVc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International<sup id="xdx_F46_zk6oJNGhxW06">(1)</sup></span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,692</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,422</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_zPlA0WRBQa3i" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,457</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F06_ztxyTbwGLl0j">(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F17_z6qoczFUDlLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International revenues are defined as revenues generated from sales to customers outside of the U. S. and Canada.</span></td> </tr></table> <p id="xdx_8AC_z4ytyo7jp2Id" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One customer accounted for approximately 15% of the Company’s total revenues during the six months ended June 30, 2026. Revenue from this customer primarily related to a one-time sale and is not expected to represent a recurring source of revenue. No other customer accounted for 10% or more of the Company’s total revenues during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zkjCuLWFsuNi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table details total revenues by major geographic area for the periods presented:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z3B16izuVpz3" style="display: none">Schedule of Total Revenues by Major Geographical Area</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260401__20260630_zpu6HCvcfEY5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260630_zHjUJKmnymN1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__country--US_z16uJZ3Nyb49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">58,028</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">85,171</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__country--CA_zK1fIbUeFGjl" style="vertical-align: bottom; background-color: White"> <td>Canada</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">864</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_hsrt--StatementGeographicalAxis__custom--InternationalMember_zaxUHQwQOVc2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International<sup id="xdx_F46_zk6oJNGhxW06">(1)</sup></span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,692</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,422</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Revenues_zPlA0WRBQa3i" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,457</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F06_ztxyTbwGLl0j">(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F17_z6qoczFUDlLl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International revenues are defined as revenues generated from sales to customers outside of the U. S. and Canada.</span></td> </tr></table> 58028 85171 384 864 4692 5422 63104 91457 <p id="xdx_847_eus-gaap--InventoryPolicyTextBlock_z5pxUajfwPV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_869_z26q4GoIzKT5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Inventories</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consisting of finished goods are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete, spoiled, or in excess of future demand. The Company records an impairment that is charged directly to cost of revenue when it determines the product is obsolete, spoiled or in excess of future demand, and the Company will not be able to sell it at a normal profit above it carrying value. During the three months ended June 30, 2026, the Company determined that $<span id="xdx_90A_eus-gaap--InventoryWriteDown_c20260401__20260630_zZmHinvUCa23" title="Impaired due to obsolesce">42,372</span> was impaired due to obsolesce and recorded the impairment to inventory write-off included in cost of revenue in the accompanying unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 42372 <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zbhxsIyR7Skd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zyonkRAUs5N8">Recently Issued Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2024-03<i>, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-04) — Disaggregation of Income Statement Expenses (“ASU 2024-03”)</i>, and in January 2025, the FASB issued ASU 2025-01 — <i>Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date </i>(“ASU 2025-01”). ASU 2024-03 requires additional disclosure of the nature of expenses included in the statement of operations as well as disclosures about specific types of expenses included in the expense captions presented in the statement of operations. ASU 2024-03, as clarified by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. Both early adoption and retrospective application are permitted. The Company is currently assessing the impact of this ASU; however expects to enhance expense disclosures based on the new requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2025, the FASB issued ASU 2025-11 <i>– Interim Reporting (Topic 270): Narrow-Scope Improvements</i> (“ASU 2025-11”). ASU 2025-11 clarifies the interim reporting guidance in the Accounting Standards Codification (“ASC”), adding a comprehensive list of required interim disclosures and a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim periods within annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating these new disclosure requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other ASUs issued and not yet effective as of June 30, 2026, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s current or future financial position or results of operations.</span></p> <p id="xdx_80F_ecustom--RecapitalizationDisclouserTextBlock_z2tPwBUHONbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. <span id="xdx_829_zJC5ZmPPlXBk">Reverse Recapitalization</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2024, PowerUp Acquisition Corp. (“PowerUp”) entered into Merger Agreement with PowerUp Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), the New Sponsor, Stephen Quesenberry, in the capacity as the seller representative, and Aspire Biopharma, Inc., a Puerto Rico corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025 prior to the time of the consummation of the Reverse Recapitalization (the “Closing Date”), Merger Sub merged with and into Aspire Biopharma, Inc., with Aspire Biopharma, Inc. being the surviving company. After giving effect to the Reverse Recapitalization, Aspire Biopharma, Inc. became a wholly-owned subsidiary of Aspire Biopharma Holdings, Inc., a Delaware corporation (f/k/a PowerUp Acquisition Corp.) (“New Aspire”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the Merger Agreement, PowerUp migrated out of the Cayman Islands and domesticated as a Delaware corporation. Also, prior to the Closing Date, Aspire Biopharma, Inc. deregistered as a Puerto Rican entity and domesticated as a Delaware corporation (the “Aspire Domestication”). In connection with the Aspire Domestication, all issued and outstanding shares of Aspire’s pre-domestication voting common stock, Series A preferred stock, and any unconverted warrants automatically converted, on a one-for-one basis, into shares of the post-domesticated entity’s common stock, Series A preferred stock, and warrants, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Reverse Recapitalization was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, PowerUp, who is the legal acquirer, was treated as the “acquired” company for financial reporting purposes and Aspire Biopharma, Inc. was treated as the accounting acquirer. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of a capital transaction in which Aspire issued stock for the net assets of PowerUp. The net assets of PowerUp will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Reverse Recapitalization will be those of Aspire Biopharma, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transaction Proceeds</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the closing of the Reverse Recapitalization, the Company received gross proceeds of $<span id="xdx_900_ecustom--BusinessCombinationGrossProceedsAmount_c20250101__20251231_za460QSD5eX9" title="Business combination gross proceeds amount">811,370</span>, offset by total transaction costs of $<span id="xdx_904_ecustom--BusinessRecapitalizationCostOfAcquiredEntityTransactionCostsAmount_iN_di_c20250101__20251231_zSaeNK2TVSSl" title="Transaction costs">545,543</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--ReconcilesTheElementsOfTheBusinessCombinationTableTextBlock_zcDW3UlhoF04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the elements of the Reverse Recapitalization to the unaudited consolidated statement of cash flows and the unaudited consolidated statement of changes in stockholders’ deficit:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B3_zxkNuTDDZKVa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Reconciles the Elements of the Business Combination</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20250101__20251231_zxrPBqD2aDDk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--BusinessCombinationGrossProceedsAmount_zYvzqfikWk7h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Cash-trust and cash, net of redemptions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">811,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessAcquisitionCostOfAcquiredEntityTransactionCostsAmount_iI_za7x4UpaYgG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: transaction costs, paid</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(545,543</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--BusinessRecapitalizationCostOfAcquiredEntityTransactionCostsProceeds_iT_zMrDe4CeOTTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net proceeds from the Reverse Recapitalization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265,827</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesCombined_iN_di_zsqE4ZrkaH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Accounts payable, Accrued liabilities and Other current liabilities combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,577,057</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--PromissoryNoteFeeRelatedPartyCombined_iN_di_zooIFH3If4Th" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Promissory note fee – related party combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--SubscriptionAgreementLoansCombined_iN_di_zx6iXFjaKxI8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Subscription agreement loans combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,828,098</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--LoanAndTransferNotePayableCombined_iN_di_zlh9ooMEUTQ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Loan and transfer notes payable combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(499,214</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ForwardPurchaseAgreementLiabilityCombined_iN_di_zpPcwwbiXtEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Forward purchase agreement liability combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49,034</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--BusinessCombinationOtherNet_iN_di_z6EnHhPY7G89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Add: Other assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">85,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ReverseRecapitalizationNet_iT_z1r3TUNaRSd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Reverse Recapitalization, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,602,576</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A6_z8cZoZcvC2wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ConsummationOfTheBusinessCombinationTableTextBlock_zqHGDWNJmJof" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarized the number of shares of common stock issued and outstanding immediately following the consummation of the Reverse Recapitalization:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B7_z6nmtSyeckM3" style="display: none">Schedule of Consummation of the Business Combination</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20250217__20250217_zmTgEBAuSB8a" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--BusinessCombinationPowerupClassCommonStockOutstandingPriorToBusinessCombination_zGvYmeqBRHTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">PowerUp Class A common stock, outstanding prior to the Reverse Recapitalization</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">7,765,144</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRedemptionOfPowerupClassCommonStock_za9354EOwng8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Redemption of PowerUp Class A common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(507,631</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--BusinessCombinationClassCommonStockOfPowerup_iT_zVwuFyB59Xs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Class A common stock of PowerUp</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,257,513</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationPowerupClassBCommonStockOutstandingPriorToBusinessCombination_zv7qm0f5f9n9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PowerUp Class B common stock, outstanding prior to the Reverse Recapitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ReverseRecapitalizationClassCommonStockBeforeReverseSplit_iT_zjEpCJG04Yq" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Reverse Recapitalization Class A common stock, before giving effect to Reverse Splits (see <i>Note 1. Description of Organization and Business</i>)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,257,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ReverseRecapitalizationClassCommonStockAfterReverseSplit_iT_ztYvAw2NpSc5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse Recapitalization Class A common stock, after giving effect to the Reverse Splits (see <i>Note 1. Description of Organization and Business</i>)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,048</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationIssuanceOfSharesRelatedWorkingCapitalAgreements_zMCfq0c8FKC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of shares related to working capital agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,125</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationAspireBiopharmaIncShares_z2dM5eueXNQc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Aspire Biopharma, Inc. shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29,167</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockImmediatelyAfterReverseRecapitalization_iT_zevi1NrOogL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock immediately after the Reverse Recapitalization, after giving effect to the Reverse Splits (see <i>Note 1. Description of Organization and Business</i>)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">38,340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zlDi15YHs8t1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfNumberOfSharesAndConversionRatioTableTextBlock_zPOZFCnSpe5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the number of Aspire Biopharma, Inc. shares after giving effect to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zhaVsPudLHG5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Number of Shares Conversion Ratio</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aspire Biopharma, Inc. shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aspire’s shares after conversion ratio</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock issued to existing Aspire Biopharma, Inc. shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember__custom--ClassofStockAxis__custom--CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember_zJcMgrMEtI7" style="width: 16%; text-align: right" title="Common Stock issued to existing Aspire Biopharma, Inc Shareholders">443,185</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__custom--ConversionRatioMember__custom--ClassofStockAxis__custom--CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember_zos6NFb6ZRlf" style="width: 16%; text-align: right" title="Common Stock issued to existing Aspire Biopharma, Inc Shareholders">27,781</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Common stock obligation shares issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__custom--ClassofStockAxis__custom--CommonStockObligationSharesIssuedMember_zOHA6BBapUv4" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock obligation shares issued"><span style="-sec-ix-hidden: xdx2ixbrl0820">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__custom--ConversionRatioMember__custom--ClassofStockAxis__custom--CommonStockObligationSharesIssuedMember_zjVoin9zEdmi" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock obligation shares issued">1,386</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Number of common shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zw9s3dD3B4ub" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares">443,185</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__custom--ConversionRatioMember_zqYGpCulfQXf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares">29,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zGX8fARYV6z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Public and private placement warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zHSlq2NRpTld" title="Number of warrants to purchase shares issued">14,374,969</span> Public Warrants issued at the time of the PowerUp’s initial public offering, and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOMS42LlEFug" title="Number of warrants to purchase shares issued">8,199</span> private placement warrants, after giving effect to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>), issued in connection with the private placement at the time of the PowerUp’s initial public offering (the “Private Placement Warrants”) which remained outstanding and became warrants of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 811370 -545543 <p id="xdx_892_ecustom--ReconcilesTheElementsOfTheBusinessCombinationTableTextBlock_zcDW3UlhoF04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the elements of the Reverse Recapitalization to the unaudited consolidated statement of cash flows and the unaudited consolidated statement of changes in stockholders’ deficit:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B3_zxkNuTDDZKVa" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Reconciles the Elements of the Business Combination</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20250101__20251231_zxrPBqD2aDDk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--BusinessCombinationGrossProceedsAmount_zYvzqfikWk7h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Cash-trust and cash, net of redemptions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">811,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessAcquisitionCostOfAcquiredEntityTransactionCostsAmount_iI_za7x4UpaYgG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: transaction costs, paid</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(545,543</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--BusinessRecapitalizationCostOfAcquiredEntityTransactionCostsProceeds_iT_zMrDe4CeOTTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net proceeds from the Reverse Recapitalization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265,827</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--AccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilitiesCombined_iN_di_zsqE4ZrkaH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Accounts payable, Accrued liabilities and Other current liabilities combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,577,057</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--PromissoryNoteFeeRelatedPartyCombined_iN_di_zooIFH3If4Th" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Promissory note fee – related party combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--SubscriptionAgreementLoansCombined_iN_di_zx6iXFjaKxI8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Subscription agreement loans combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,828,098</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--LoanAndTransferNotePayableCombined_iN_di_zlh9ooMEUTQ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Loan and transfer notes payable combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(499,214</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ForwardPurchaseAgreementLiabilityCombined_iN_di_zpPcwwbiXtEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: Forward purchase agreement liability combined</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(49,034</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--BusinessCombinationOtherNet_iN_di_z6EnHhPY7G89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Add: Other assets, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">85,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ReverseRecapitalizationNet_iT_z1r3TUNaRSd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Reverse Recapitalization, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,602,576</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 811370 -545543 265827 1577057 1000000 1828098 499214 49034 -85000 -4602576 <p id="xdx_89A_ecustom--ConsummationOfTheBusinessCombinationTableTextBlock_zqHGDWNJmJof" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarized the number of shares of common stock issued and outstanding immediately following the consummation of the Reverse Recapitalization:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B7_z6nmtSyeckM3" style="display: none">Schedule of Consummation of the Business Combination</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20250217__20250217_zmTgEBAuSB8a" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--BusinessCombinationPowerupClassCommonStockOutstandingPriorToBusinessCombination_zGvYmeqBRHTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">PowerUp Class A common stock, outstanding prior to the Reverse Recapitalization</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">7,765,144</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--BusinessCombinationRedemptionOfPowerupClassCommonStock_za9354EOwng8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Redemption of PowerUp Class A common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(507,631</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--BusinessCombinationClassCommonStockOfPowerup_iT_zVwuFyB59Xs3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Class A common stock of PowerUp</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,257,513</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationPowerupClassBCommonStockOutstandingPriorToBusinessCombination_zv7qm0f5f9n9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">PowerUp Class B common stock, outstanding prior to the Reverse Recapitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ReverseRecapitalizationClassCommonStockBeforeReverseSplit_iT_zjEpCJG04Yq" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Reverse Recapitalization Class A common stock, before giving effect to Reverse Splits (see <i>Note 1. Description of Organization and Business</i>)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,257,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ReverseRecapitalizationClassCommonStockAfterReverseSplit_iT_ztYvAw2NpSc5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse Recapitalization Class A common stock, after giving effect to the Reverse Splits (see <i>Note 1. Description of Organization and Business</i>)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,048</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationIssuanceOfSharesRelatedWorkingCapitalAgreements_zMCfq0c8FKC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance of shares related to working capital agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,125</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationAspireBiopharmaIncShares_z2dM5eueXNQc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Aspire Biopharma, Inc. shares</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29,167</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CommonStockImmediatelyAfterReverseRecapitalization_iT_zevi1NrOogL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock immediately after the Reverse Recapitalization, after giving effect to the Reverse Splits (see <i>Note 1. Description of Organization and Business</i>)</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">38,340</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7765144 -507631 7257513 7257513 6048 3125 29167 38340 <p id="xdx_89B_ecustom--ScheduleOfNumberOfSharesAndConversionRatioTableTextBlock_zPOZFCnSpe5b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the number of Aspire Biopharma, Inc. shares after giving effect to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BC_zhaVsPudLHG5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Number of Shares Conversion Ratio</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aspire Biopharma, Inc. shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aspire’s shares after conversion ratio</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Common stock issued to existing Aspire Biopharma, Inc. shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember__custom--ClassofStockAxis__custom--CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember_zJcMgrMEtI7" style="width: 16%; text-align: right" title="Common Stock issued to existing Aspire Biopharma, Inc Shareholders">443,185</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__custom--ConversionRatioMember__custom--ClassofStockAxis__custom--CommonStockIssuedToExistingAspireBiopharmaIncShareholdersMember_zos6NFb6ZRlf" style="width: 16%; text-align: right" title="Common Stock issued to existing Aspire Biopharma, Inc Shareholders">27,781</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Common stock obligation shares issued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember__custom--ClassofStockAxis__custom--CommonStockObligationSharesIssuedMember_zOHA6BBapUv4" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock obligation shares issued"><span style="-sec-ix-hidden: xdx2ixbrl0820">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__custom--ConversionRatioMember__custom--ClassofStockAxis__custom--CommonStockObligationSharesIssuedMember_zjVoin9zEdmi" style="border-bottom: Black 1pt solid; text-align: right" title="Common Stock obligation shares issued">1,386</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Number of common shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zw9s3dD3B4ub" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares">443,185</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250217__20250217__us-gaap--StatementEquityComponentsAxis__custom--ConversionRatioMember_zqYGpCulfQXf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares">29,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 443185 27781 1386 443185 29167 14374969 8199 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zYfbxkZtrcr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. <span id="xdx_823_z8qj0yEM0QU1">Related Party Transaction</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loan and transfer agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to finance transaction costs in connection with the Reverse Recapitalization, the New Sponsor or an affiliate of the New Sponsor, or certain affiliates of PowerUp loaned monies for working capital purposes (“Working Capital Loans”) by entering into several Loan and Transfer Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, the Company assumed $<span id="xdx_90D_eus-gaap--Liabilities_iI_c20250217__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorAndSsvkAssociatesLlcMember_zWTBWPWaXx11" title="Liabilities">250,000</span> of liabilities related to the December 21, 2023, Loan and Transfer Agreement with the New Sponsor and SSVK Associates, LLC (“SSVK”). As of June 30, 2026, and December 31, 2025, there was $<span id="xdx_903_eus-gaap--ShortTermBorrowings_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorAndSsvkAssociatesLlcMember_zwCsxnCQJR93" title="Short term borrowings">0</span> and $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorAndSsvkAssociatesLlcMember_zlF0nw2iw1pa" title="Short term borrowings">250,000</span>, respectively, in borrowings outstanding under the agreement and included in loan and transfer notes payable-related on the accompanying unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, the Company assumed $<span id="xdx_903_eus-gaap--Liabilities_iI_c20250217__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ApogeePharmaMember_zFucRckgGkTf" title="Liabilities">50,000</span> of liabilities related to the January 9, 2024 Loan and Transfer Agreement with the New Sponsor and Apogee Pharma (“Apogee”). As of June 30, 2026 and December 31, 2025, there was $<span id="xdx_90F_eus-gaap--ShortTermBorrowings_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ApogeePharmaMember_zdHEOKaVW739" title="Short term borrowings">0</span> and $<span id="xdx_90E_eus-gaap--ShortTermBorrowings_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ApogeePharmaMember_z5UTdozkxvt6" title="Short term borrowings">50,000</span>, respectively, in borrowings outstanding under the agreement and included in loan and transfer notes payable-related party on the accompanying unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, the Company assumed $<span id="xdx_90C_eus-gaap--Liabilities_iI_c20250217__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JinalShethMember_z4fAXr7ETXYi" title="Liabilities">149,214</span> of liabilities related to the January 10, 2024 Loan and Transfer Agreement with the New Sponsor and Jinal Sheth (“Sheth”). As of June 30, 2026, and December 31, 2025, there was $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JinalShethMember_zQwsH2KXfuEi" title="Short term borrowings">0</span> and $<span id="xdx_90D_eus-gaap--ShortTermBorrowings_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JinalShethMember_zfvE17HXAyPc" title="Short term borrowings">149,214</span>, respectively, in borrowings outstanding under the agreement and included in loan and transfer notes payable-related party on the accompanying unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, the Company assumed $<span id="xdx_901_eus-gaap--Liabilities_iI_c20250217__us-gaap--TypeOfArrangementAxis__custom--SecondLoanAndTransferAgreementtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ApogeePharmaTwoMember_zojHPZ9wBSr" title="Liabilities">50,000</span> of liabilities related to the December 3, 2024 Loan and Transfer Agreement with the New Sponsor and Apogee Pharma (“Apogee 2”). As of June 30, 2026 and December 31, 2025, there was $<span id="xdx_903_eus-gaap--ShortTermBorrowings_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecondLoanAndTransferAgreementtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ApogeePharmaTwoMember_zGaIMcTkDFQa" title="Short term borrowings">0</span> and $<span id="xdx_90B_eus-gaap--ShortTermBorrowings_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecondLoanAndTransferAgreementtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ApogeePharmaTwoMember_z5sbgIxNcZJ" title="Short term borrowings">50,000</span>, respectively, in borrowings outstanding under the agreement and included in loan and transfer notes payable-related party on the accompanying unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2026 and April 15, 2026, the Company entered into payment agreements with SSVK, Apogee and Sheth, to which the Company settled in cash the total balance of $<span id="xdx_902_eus-gaap--LoansPayableCurrent_iI_c20260414__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JinalShethMember_zyDIJPS1uxH8" title="Loan and transfer notes payable"><span id="xdx_900_eus-gaap--LoansPayableCurrent_iI_c20260415__us-gaap--TypeOfArrangementAxis__custom--LoanAndTransferAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JinalShethMember_zF9hOPWDfKKb" title="Loan and transfer notes payable">499,214</span></span>, including applicable interest and fees, owed under the Loan and transfer Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2024, PowerUp entered into four separate Subscription Agreements (each, a “First Subscription Agreement”) with the New Sponsor, Visiox, VKS Capital, LLC, an affiliate of, and an entity under common control with, the New Sponsor (the “Affiliate”), and four separate investors (each, an “Investor”), whereby the Investors collectively contributed to New Sponsor a total of $<span id="xdx_909_eus-gaap--ProceedsFromContributedCapital_c20240305__20240305__us-gaap--TypeOfArrangementAxis__custom--FirstSubscriptionAgreementMember_zPYeKZCI9dx3" title="Sponsor contribution">1,000,000</span> (the “First Contribution”). The New Sponsor utilized the First Contribution to support PowerUp’s previously anticipated merger with Visiox by funding certain obligations to Visiox pursuant to the Secured Convertible Promissory Note, dated December 1, 2023, issued by Visiox to the New Sponsor (the “Visiox Convertible Note”) (together, all loans and advances, the “March Loan”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2024, PowerUp entered into four separate Subscription Agreements (each, a “Second Subscription Agreement”) with the New Sponsor, the Affiliate, and four separate Investors, whereby, the Investors collectively contributed to the New Sponsor a total of $<span id="xdx_908_eus-gaap--ProceedsFromContributedCapital_c20240509__20240509__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementsMember_zybofBx5b4Ha" title="Sponsor contribution">500,000</span> (the “Second Contribution”) and, in turn, the New Sponsor loaned $<span id="xdx_904_eus-gaap--PaymentsForLoans_c20240509__20240509__us-gaap--TypeOfArrangementAxis__custom--SecondSubscriptionAgreementsMember_zxRXxjFxtEXe" title="Payments for loans">500,000</span> to PowerUp (the “May Loan”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PowerUp accounted for the First and Second Subscription Agreements under ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”) and concluded that bifurcation of a single derivative that comprises all of the fair value of the conversion feature(s) (i.e., derivative instrument(s)) is not necessary under ASC 815-15-25-7 through 25-10. As a result, all debt proceeds received from Investor have been recorded using the relative fair value method of accounting under ASC 470, Debt (“ASC 470”). Pursuant to ASC 470, the Company recorded the fair value of the subscription liability on the unaudited condensed consolidated balance sheets using the relative fair value method. The initial fair value of the subscription liability at issuance was estimated using a Black Scholes and Probability Weighted Expected Return Model. At the close of the Reverse Recapitalization, 1,458 of commitment fee shares, after giving effect to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>), owing to the Investors under these agreements were transferred by affiliates to the Investors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, the Company assumed $<span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20250217__us-gaap--TypeOfArrangementAxis__custom--FirstSubscriptionAgreementMember_ziZkZFWoE4Rb" title="Debt">1,500,000</span> of debt under the First Subscription and Second Subscription Agreements. For the three and six months ended June 30, 2026, the Company incurred $<span id="xdx_903_ecustom--DebtIncurredInInterestExpense_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--FirstAndSecondSubscriptionAgreementMember_zJCLwGQRyue5" title="Debt incurred in interest expense">0</span> and $<span id="xdx_907_ecustom--DebtIncurredInInterestExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--FirstAndSecondSubscriptionAgreementMember_z9axchxudIC4" title="Debt incurred in interest expense">250,000</span>, respectively, in interest expense on the Subscription Agreements which is included in accrued expenses on the accompanying unaudited condensed consolidated balance sheet. In January 2026 the Subscription Agreement Loans, along with $<span id="xdx_900_ecustom--DebtInterestAndFees_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--FirstAndSecondSubscriptionAgreementMember_z34wADrahD7c" title="Debt interest and fees">266,917</span> of interest and fees, were converted into common stock of the Company. At June 30, 2026, and December 31, 2025, $<span id="xdx_90C_eus-gaap--NotesPayable_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--FirstAndSecondSubscriptionAgreementMember_zbx3aI0QNDZj" title="Loan payable">0</span> and $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--FirstAndSecondSubscriptionAgreementMember_zsuTO3pv266h" title="Loan payable">1,500,000</span>, respectively, were outstanding under these agreements and is included in subscription agreement loan balance on the unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promissory Note Fee – related party</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 2, 2024, after Aspire and PowerUp had signed their BCA in August 2024, PowerUp entered into a Promissory Note Fee Agreement with the Sponsor, Srirama Associates LLC (the “Promissory Note Fee Agreement”). Pursuant to the Promissory Note Fee Agreement, PowerUp and the Sponsor agreed that the Sponsor took a significant risk on behalf of the Company by entering into the Visiox Promissory Note in exchange for payment of the Original Promissory Note Fee, and that the Sponsor should be compensated for that risk despite the termination of the right to receive the Original Promissory Note Fee as a result of the termination of the proposed merger with previous target, Visiox. As consideration for the foregoing, PowerUp agreed to pay Sponsor a modified promissory note fee of $<span id="xdx_902_eus-gaap--LoansPayable_iI_c20241002__us-gaap--TypeOfArrangementAxis__custom--ModifiedPromissoryNoteFeeAgreementMember_zX3zz1mbzj67" title="Loans payable">1,000,000</span> (the “Modified Promissory Note Fee”) upon the successful closing of a merger with Aspire.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2026, Srirama Associates, LLC filed a lawsuit in the Superior Court of the State of Delaware alleging breach of contract in connection with the modified Promissory Note Fee Agreement. The complaint sought not less than $<span id="xdx_902_eus-gaap--LossContingencyDamagesSoughtValue_c20260430__20260430_z744oLQasfo4" title="Loss contingency, damages sought, value">1,000,000</span> in damages, plus interest and costs. The Company disputed the claim and filed a motion to dismiss on May 11, 2026. On June 29, 2026, the claim was dismissed with prejudice by the Superior Court of the State of Delaware and the liability of $<span id="xdx_90B_eus-gaap--LossContingencyDamagesSoughtValue_c20260629__20260629_z7ES382iv52a" title="Loss contingency, damages sought, value">1,000,000</span> was written off and included in gain on extinguishment of debt on the unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Due to affiliate</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, in conjunction with the closing of the business combination, the Company had placed on its books $<span title="Due to affiliate"><span id="xdx_90C_eus-gaap--AdministrativeFeesExpense_c20250217__20250217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z38EFFFBkVcl" title="Administrative fees expense">353,679</span></span> of liabilities claimed by the Sponsor of PowerUp, Srirama Associates, LLC, for alleged administrative services fees. Based on the legal doctrine of res judicata (as a consequence of the above-referenced Sponsor lawsuit being dismissed with prejudice) on June 29, 2026, and after careful investigation of the alleged basis for the claimed administrative services fees, $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20250217__20250217_zY5YUAyBfHu5" title="Gain (loss) on extinguishment of debt">353,679</span> was written off and included in gain (loss) on extinguishment of debt on the unaudited condensed consolidated statements of operations. As of June 30, 2026 and December 31, 2025, the balance of $<span id="xdx_903_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AffiliatesMember_zWTrwJ5bmtph" title="Due to affiliate">0</span> and $<span id="xdx_90C_eus-gaap--OtherLiabilitiesCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AffiliatesMember_ze3YkKxtmIjl" title="Due to affiliate">353,679</span>, respectively, is recorded in due to affiliate on the unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes payable – related party</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years 2024 and 2023, Aspire Biopharma, Inc. incurred expenses and costs related to officer and director compensation, rental of office space, reimbursable expenses paid by affiliates and non-interest bearing working capital loans. On September 27, 2024, to formalize the related party working capital advances, Aspire Biopharma, Inc. issued three nonconvertible <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240927__20240927_zPHlsizQwmGl" title="Debt interest rate">20</span>% original issues discount (“OID”) notes payable to related parties for a total face value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20240927_zBCYRBXJyPE4" title="Principal amount">1,066,391</span>. The notes were due the earlier of June 27, 2025 (9 months from issuance), or (ii) the date that the Company receives gross proceeds of at least $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240927__20240927_zjyEgUvgUJU2" title="Gross proceeds">2,500,000</span> in an offering of its debt or equity securities (a “Qualified Offering”). The notes do not bear interest but have a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240927_zrqyfKpcY326" title="Debt interest stated percentage">5</span>% exit fee payable on maturity or repayment. The notes had original issuance discounts totaling $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20240927_zzF1ZNEonlu" title="Debt unamortized discount">213,278</span> and are unsecured. Pursuant to the February 18, 2025 subordination agreement between two note holders and Cobra, payments will not be made on the matured notes until full payment of the Cobra obligation (<i>See Note 5. Convertible Notes</i>). The balance of $<span id="xdx_90C_eus-gaap--RepaymentsOfRelatedPartyDebt_c20260101__20260630__us-gaap--AwardDateAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_zqPW7aQCU8A" title="Repayments of debt">591,692</span> on the notes payable-related party was repaid during the six months ended June 30, 2026. For the three months ended June 30, 2026, and 2025, total amortized debt discount of $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_c20260401__20260630__us-gaap--AwardDateAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_zkvh8ZgCO9" title="Amortized debt discount">0</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20250401__20250630__us-gaap--AwardDateAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_zFcIsAnY6xpe" title="Amortized debt discount">68,733</span>, respectively, and for the six months ended June 30, 2026 and 2025, total amortized debt discount $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_c20260101__20260630__us-gaap--AwardDateAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_zA5LIz0CGJcj" title="Amortized debt discount">0</span> and $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20250630__us-gaap--AwardDateAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_zWiBGJmXB0A9" title="Amortized debt discount">139,052</span>, respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2024, the Company issued one non-convertible <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20241231__20241231_zqFY79cB7M6b" title="Debt interest rate">20</span>% OID note payable for working capital to a related party for a total face value of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231_zQLZitEvN2Uh" title="Principal amount">279,878</span>. The note is due the earlier of September 30, 2025, (9 months from issuance); or (ii) the date that the Company receives gross proceeds of at least $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241231__20241231_z08DJ9ZhwkT1" title="Gross proceeds">2,500,000</span> in an offering of its debt or equity securities (a “Qualified Offering”). The note does not bear interest but has a <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231_zuV4DLcFieXa" title="Debt interest stated percentage">5</span>% exit fee payable on maturity or repayment and had original issuance discounts totaling $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20241231_zKAYBQ3QPYZe" title="Debt unamortized discount">46,646</span> and was unsecured. The balance of $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20260101__20260331__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_zZYAJiNjcFek" title="Repayments of debt">293,872</span> on the notes payable- related party was repaid during the six months ended June 30, 2026. For the three months ended June 30, 2026, and 2025, total amortized debt discount of $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_c20260401__20260630__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_z3Vr8Ls6cbW4" title="Amortized debt discount">0</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20250401__20250630__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_zXaJEGSfvP3b" title="Amortized debt discount">4,121</span>, respectively, and for the six months ended June 30, 2026, and 2025, total amortized debt discount of $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20260101__20260630__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_z9RaNW2Lodeb" title="Amortized debt discount">0</span> and $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20250101__20250630__us-gaap--AwardDateAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_zoGh0oW3FPpe" title="Amortized debt discount">8,379</span>, respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zHVsg3b6oQJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects the total balances of the Notes payable – related party for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B2_zy6JUaLDhiDi" style="display: none">Schedule of Note Issuance</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z67nDRt7hLp9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zPjqQqARqmfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_z613HGJRYRLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">September 27, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">591,692</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_zogwUaKiZCc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">293,872</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayableCurrent_iI_zlVj7djwL2k1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">885,564</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zllwJeUCnjnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 0 250000 50000 0 50000 149214 0 149214 50000 0 50000 499214 499214 1000000 500000 500000 1500000 0 250000 266917 0 1500000 1000000 1000000 1000000 353679 353679 0 353679 0.20 1066391 2500000 0.05 213278 591692 0 68733 0 139052 0.20 279878 2500000 0.05 46646 293872 0 4121 0 8379 <p id="xdx_896_eus-gaap--ScheduleOfDebtTableTextBlock_zHVsg3b6oQJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects the total balances of the Notes payable – related party for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B2_zy6JUaLDhiDi" style="display: none">Schedule of Note Issuance</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Issuance date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z67nDRt7hLp9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zPjqQqARqmfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--SeptemberTwentySevenTwoThousandTwentyFourMember_z613HGJRYRLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">September 27, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">591,692</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesPayableCurrent_iI_hus-gaap--DebtInstrumentAxis__custom--DecemberThirtyFirstTwoThousandTwentyFourMember_zogwUaKiZCc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">293,872</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayableCurrent_iI_zlVj7djwL2k1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">885,564</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 591692 293872 885564 <p id="xdx_804_eus-gaap--ShortTermDebtTextBlock_zmXrsrzrTzh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. <span id="xdx_82D_zl4acJ8r2cph">Convertible Notes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>February 2025 Securities Purchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2025, the Company entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) with Cobra Alternative Capital Strategies, LLC, an entity controlled by the Company’s former Director of Investor Relations, Lance Friedman, whose services were provided through a consulting agreement with Blackstone Capital Advisors, Inc. that was terminated effective February 17, 2025, and Target Capital X LLC (collectively, the “Investors”). Under the Securities Purchase Agreement, the Company issued <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20250217__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CobraAlternativeCapitalStrategiesLLCMember_zbuL8sCxdL17" title="Original issue discount, percentage">20</span>% original issue discount senior secured convertible debentures (“February 2025 Convertible Debentures,”) in an aggregate principal amount of $<span id="xdx_907_eus-gaap--DerivativeNotionalAmount_iI_c20250217__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CobraAlternativeCapitalStrategiesLLCMember_zozOTRFO2V61" title="Aggregate principal amount">3,750,000</span> which included a <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20250217__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CobraAlternativeCapitalStrategiesLLCMember_zRjZwyNH3jL6" title="Original issue discount, percentage">20</span>% OID. The conversion price per share of each Debenture is equal to <span id="xdx_90E_eus-gaap--DerivativeAverageVariableInterestRate_iI_pid_dp_c20250217__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CobraAlternativeCapitalStrategiesLLCMember_zhxGSZfXlduf" title="Conversion price per share">92.5</span>% of the lowest daily VWAP (as defined in the Debentures), provided that no conversion may be at a price per share less than the floor price of $<span id="xdx_907_ecustom--ConversionFloorPricePerShare_iI_pid_c20250217__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CobraAlternativeCapitalStrategiesLLCMember_zA5U5o8Kgt46" title="Conversion floor price per share">4.00</span> per share. At the close of the Reverse Recapitalization, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250217__20250217__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--CobraAlternativeCapitalStrategiesLLCMember_zzv33Fdhe5Il" title="Commitment fee shares to investors">1,755</span> of commitment fee shares, after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>), was due to the Investors under these agreements were transferred by Affiliates to the Investors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company analyzed the Securities Purchase Agreement under ASC 480 and ASC 815 and concluded that bifurcation of a single derivative that comprises all of the fair value of the conversion feature(s) (i.e., derivative instrument(s)) is not necessary. As a result, all debt proceeds received have been recorded using the fair value method of accounting under ASC 825, Fair Value Measurement (“ASC 825”). Pursuant to ASC 825, the Company recorded the fair value of the subscription liability on the unaudited condensed consolidated balance sheet using the fair value method. The initial fair value of the subscription liability at issuance was estimated using a Monte Carlo Model. In August and September 2025, the Company repaid a total of $<span id="xdx_90F_eus-gaap--RepaymentsOfConvertibleDebt_c20250801__20250831__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPoUn79MoLGa" title="Repayment of convertible debt"><span id="xdx_90E_eus-gaap--RepaymentsOfConvertibleDebt_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYYGLUKtvDXg" title="Repayment of convertible debt">3,032,645</span></span> of the February 2025 Convertible Debentures. For the three and six months ended June 30, 2026, the change in fair value was $<span id="xdx_907_ecustom--ChangeInFairValueOfDerivativeLiabilities_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSLMnEWHVdIj" title="Change in fair value of derivatives">0</span> and $<span id="xdx_908_ecustom--ChangeInFairValueOfDerivativeLiabilities_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQkr9ZCFJ5cj" title="Change in fair value of derivatives">211,443</span>, respectively. For the three and six months ended June 30, 2025, the change in fair value was $<span id="xdx_908_ecustom--ChangeInFairValueOfDerivativeLiabilities_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZ4CVnMGF6Ol" title="Change in fair value of derivatives">187,500</span> and $<span id="xdx_908_ecustom--ChangeInFairValueOfDerivativeLiabilities_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZ8UnWdYnj24" title="Change in fair value of derivatives">274,038</span>, respectively, and is included the in the change in fair value of derivative liabilities and convertible notes on the unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2026, the remaining balance of $<span id="xdx_908_eus-gaap--RepaymentsOfConvertibleDebt_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znvjjTu62htg" title="Repayment of convertible debt">943,801</span> was converted into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zx9w88xorjMe" title="Debt conversion, shares issued">974</span> shares of Series A Convertible Preferred Stock. At June 30, 2026 and December 31, 2025, the fair value of $<span id="xdx_900_eus-gaap--ConvertibleDebtCurrent_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zf566cu3UICl" title="Convertible Notes">0</span> and $<span id="xdx_906_eus-gaap--ConvertibleDebtCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZjhZmmBRon2" title="Convertible Notes">1,146,236</span>, respectively, of the Securities Purchase Agreement is included in convertible notes on the accompanying unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August 2025 Securities Purchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2025, the Company entered into a Securities Purchase Agreement (the “August Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers certain notes in an aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zPgAXV6pq4Cj" title="Aggregate principal amount">9,687,500</span> for a subscription price of $<span id="xdx_900_ecustom--SubscriptionPrice_iI_c20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zGeMssllEdW3" title="Subscription price">7,750,000</span> (the “August 2025 Notes”) with a maturity date of <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zB5XeblicZA8" title="Maturity date">February 19, 2026</span>. The August 2025 Notes have a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20250818__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zbwtckVRuqC" title="Original issue discount, percentage">20</span>% OID of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zc7xxUY1jssc" title="Original issues discount">1,937,500</span> which is included in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20250819__us-gaap--TypeOfArrangementAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zfqCA5CV0kM6" title="Aggregate principal amount">9,687,500</span> and do not bear an interest rate except for instances of default. Of the $<span id="xdx_907_ecustom--SubscriptionPrice_iI_c20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zGk26wFZglTa" title="Subscription price">7,750,000</span> total funding (before transaction expenses and debt repayments) under the Securities Purchase Agreement, $<span id="xdx_901_ecustom--SubscriptionPrice_iI_c20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--FirstTrancheMember_zqKEu35BxLJd" title="Subscription price">4,500,000</span> was funded on August 19, 2025 (the “first Tranche”), $<span id="xdx_90D_ecustom--SubscriptionPrice_iI_c20250922__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--SecondTrancheMember_zd9WgpZrAiyj" title="Subscription price">1,000,000</span> was funded on September 22, 2025 (the “Second Tranche”), and the balance of $<span id="xdx_90C_ecustom--SubscriptionPrice_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--ThirdTrancheMember_z0OR8VqhUkVf" title="Subscription price">2,250,000</span> (the “Third Tranche”) was funded on September 30, 2025. The August 2025 Notes are convertible into up to an aggregate of <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250819__20250819__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveSecuritiesPurchaseAgreementMember_zMmCf34A2Ysj" title="Shares issuable upon conversion">122,648</span> shares of common stock after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>) (the “Conversion Shares”) subject to certain conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2025, a total value of $<span id="xdx_90E_eus-gaap--DebtConversionOriginalDebtAmount1_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveNotesMember_zbFD4gmDPNVj" title="Convertible notes amount converted">9,523,683</span> of convertible notes were converted into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--AugustSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--AugustTwentyTwentyFiveNotesMember_zCQrLFeTsnsi" title="Shares issued upon note conversion">73,998</span> shares of common stock of the Company after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>). The remaining debt of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIqd9tJWpOFe" title="Remaining debt converted into common stock, value">163,817</span> was converted into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT710jScX5h3" title="Remaining debt converted into common stock, shares">1,625</span> shares of common stock in January 2026 after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>). At June 30, 2026, and December 31, 2025, the balance of the August 2025 Notes, net of unamortized debt discount was $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20260630_zm7k1wpucZdi">0</span> and $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20251231_z8TIQSO2kW5g">144,240</span>, respectively, and is included in convertible notes on the unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January 2026 Securities Purchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 26, 2026, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers certain debentures in an aggregate principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20260126__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zmK7FBUt2Fw5" title="Principal amount">2,173,913</span> for a subscription price of $<span id="xdx_90A_eus-gaap--DebtCurrent_iI_c20260126__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zneRkeLliygc" title="Subscription price">2,000,000</span> (the “Debentures”) with a maturity date of <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_c20260126__20260126__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zzUZ45JhGsya" title="Maturity date">April 23, 2026</span>. The Notes have an <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20260126__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zGLVSwX1Z7y6" title="Original issue discount percentage">8</span>% original issue discount and did bear any annual interest. The Debentures are due the sooner of (i) 90 days, or (ii) upon the Company’s receipt of gross proceeds of at least $<span id="xdx_907_eus-gaap--ProceedsFromOtherDebt_c20260126__20260126__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_z01rQvTVppjk" title="Gross proceeds">8,000,000</span> in any equity or debt financing. The Company had the option to prepay this Debenture(s) at any time after the Original Issue Date at an amount equal to the Principal Amount. The Company shall provide Holder(s) with ten (10) Business Days’ prior written notice of intention to satisfy the Debentures, whether at maturity, by prepayment, or in default. The Debentures are not convertible. In connection with the financing, the Purchasers received an aggregate of <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20260126__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zW23Bw74VK87" title="Common stock issued as incentive shares">26,333</span> shares of the Company’s common stock as incentive shares, after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>). The Debentures were repaid in February 2026. For the three and six months ended June 30, 2026, total amortized debt discounts of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zwyMwkoisBfe" title="Amortized debt discounts">0</span> and $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--DebenturesMember_zBawts3yrkLg" title="Amortized debt discounts">173,913</span>, respectively, was included in interest expense on the accompanying unaudited condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.20 3750000 0.20 0.925 4.00 1755 3032645 3032645 0 211443 187500 274038 943801 974 0 1146236 9687500 7750000 2026-02-19 0.20 1937500 9687500 7750000 4500000 1000000 2250000 122648 9523683 73998 163817 1625 0 144240 2173913 2000000 2026-04-23 0.08 8000000 26333 0 173913 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKsxclTlZjlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6. <span id="xdx_826_zsfydzZF3VCf">Commitments and Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registration Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Private Placement Warrants and Public Warrants that may be issued upon conversion of working capital loans, if any, are entitled to registration rights pursuant to a registration rights agreement dated February 17, 2022. These holders are entitled to certain demand and “piggyback” registration rights. The Company will bear the expenses incurred in connection with the filing of any such registration statements. On May 13, 2025, the Company filed a Registration Statement on Form S-1 to register <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250513__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpgRYoRfPwSa" title="Shares outstanding">2,441</span> of the outstanding <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250513__us-gaap--StatementEquityComponentsAxis__custom--PrivatePlacementWarrantsMember_z4MQzuygzULk" title="Warrants outstanding">8,199</span> Private Placement Warrants, after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>). The Registration Statement was declared effective on May 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity Line of Credit (“ELOC”) Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2025, the Company entered into a new Purchase Agreement (the “Second ELOC Agreement”) with Arena Business Solutions AG/RA SA Ltd. (“Arena”). Under the Second ELOC Agreement, the Company has the right, but not the obligation, to direct Arena to purchase up to $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20251111__20251111__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_zNMYbRaWIqL8" title="Value of shares availbale for purchase">100,000,000</span> in shares of the Company’s common stock (the “ELOC Shares”) upon satisfaction of certain terms and conditions contained in the Second ELOC Agreement, including, without limitation, an effective registration statement filed with the SEC registering the resale of the ELOC Commitment Fee Shares and additional shares to be sold to Arena from time to time under the Second ELOC Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of the Second ELOC Agreement began on November 11, 2025, and ends on the earlier of (i) the first day of the month following the 36-month anniversary of the execution date, (ii) the date on which the Investor shall have purchased the maximum amount of Second ELOC Shares, or (iii) the effective date of any written notice of termination delivered pursuant to the terms of the Second ELOC Agreement (the “Commitment Period”). <span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_pid_c20251111__20251111__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_z0cdUkLkTd7h" title="Shares issuable description">In consideration for the execution and delivery of the Second ELOC Agreement, the Company is required to issue common shares to Arena equal to $250,000 divided by the lowest 1-Trading Day VWAP of the common shares of the five (5) Trading Days immediately preceding the effectiveness of the initial registration statement (the “Commitment Fee Shares”), plus $25,000 in common shares for fees associated with the prior ELOC Agreement with the Company, based on a price equal to the lowest 1-Trading Day VWAP of the Common Shares of the five (5) Trading Days immediately preceding the date of execution and delivery of this Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251111__20251231__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_zyQEB8qZXpgi" title="Number of shares issued">2,510</span> shares of common stock after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>) to Arena in November and December 2025 and an additional <span id="xdx_903_ecustom--AdditionalPaymentOfCommitmentFeeShares_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_zopR4xEcj1P2" title="Additional payment of commitment fee shares">207</span> true up shares in January 2026, after giving effects to the Reverse Splits (<i>see Note 1. Description of Organization and Business</i>), representing payment of the commitment fee shares. For the three and six months ended June 30, 2026, the change in fair value totaled $<span id="xdx_902_ecustom--ChangeInFairValueOfDerivativeLiabilities_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_zMnEw6ey7rhe" title="Change in fair value of derivatives">275</span> and $<span id="xdx_905_ecustom--ChangeInFairValueOfDerivativeLiabilities_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_zABEY9i7Qno" title="Change in fair value of derivatives">865</span>, respectively, and was included as an expense in change in fair value of derivative liabilities and convertible notes on the unaudited condensed consolidated statement of operations, there was no change in fair value for the same period of 2025. At June 30, 2026, and December 31, 2025, the fair value of the forward purchase agreement liability related to the Second ELOC Agreement totaled $<span id="xdx_909_ecustom--ForwardPurchaseAgreementLiability_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember_zrYxJkkBMdj9" title="Forward purchase agreement liability">96,527</span> and $<span id="xdx_90A_ecustom--ForwardPurchaseAgreementLiability_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--SecondELOCAgreementMember_zv6J0TawOHi3" title="Forward purchase agreement liability">95,662</span>, respectively, and is included in forward purchase agreement liability on the accompanying unaudited condensed consolidated balance sheets. There were no issuances under the Second ELOC Agreement as of June 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Instaprin Acquisition</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2022, the Company closed on an asset purchase agreement (“APA”) of Instaprin Pharmaceuticals, Inc.’s (“Instaprin”) intangible assets, inclusive of U.S. Patent No. 62/794141, International Publication No. 2020/15460 A1 and WO 2020/150685 A1, and the Instaprin U.S. Trademark No. 86274378, trade secrets and proprietary information, all applications for any of the foregoing, commercial and scientist relationships, and any license or agreements granting rights related to the foregoing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purchase price for the Acquired Assets (as defined in the APA) was $<span id="xdx_90C_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAssetsRecognized_iI_c20220328__us-gaap--BusinessAcquisitionAxis__custom--InstaprinPharmaceuticalsIncMember_z4NtPgINa1pb" title="Assets acquired">3,628,325</span> plus interest thereon, to be paid to the SEC on behalf of Instaprin in satisfaction of the SEC’s judgment against Instaprin and its former CEO, from sales of the product, as follows: <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220328__us-gaap--BusinessAcquisitionAxis__custom--InstaprinPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveMember_z8VBIp4VlsYh" title="Business acquistion percentage">20</span>% from the first $<span id="xdx_903_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20220328__us-gaap--BusinessAcquisitionAxis__custom--InstaprinPharmaceuticalsIncMember_zBAE4JYaOqKh" title="Transaction costs">5,000,000</span> of sales and <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220328__us-gaap--BusinessAcquisitionAxis__custom--InstaprinPharmaceuticalsIncMember_zRrEsc49yqDb" title="Business acquistion description">10</span>% from sales thereafter until the entire contingent purchase price obligation is satisfied. Additionally, ten percent (10%) of the Company’s equity was to be delivered at Closing, in proportion to their equity holdings in the Company, to be issued to a Trustee for the former Instaprin Shareholders, along with an additional ten percent (10%) of the Company’s equity to be issued to Instaprin’s service providers, pursuant to a stock incentive plan to be adopted. As of June 30, 2026, the Company has not recorded the assets from the APA due to the contingent nature of the transaction and the Company has not yet adopted a stock incentive plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 10, 2026, the Company entered into a purchase agreement (the “Purchase Agreement”) with FireFish TopCo, LLC (the “Seller”, and, collectively with its Subsidiaries listed in the Purchase Agreement, “Sellers”), pursuant to which (i) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company agreed to purchase or cause certain of its Affiliates to purchase, all of the equity interests in certain of Seller’s subsidiaries of the Purchase Agreement (the aforementioned equity interests, collectively, the ‘Transferred Equity Interests”, and such subsidiaries, “Transferred Entities”), free and clear of all Liens, other than the Permitted Liens and in accordance with the applicable Local Transfer Documents and (ii) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company agreed to purchase, or cause certain of its affiliates to purchase, all of the assets of the other Business Entities as defined as Transferred Entities, DUS Operating Inc. with respect to the U.S. Enterprise and Automotive Czech with respect to the KOP Enterprise constituting the balance of the Business as defined as the business of designing, manufacturing, marketing and selling automotive systems that facilitate electronic driver control and the migration toward vehicle electrification, safety, light weighting and sustainability, as conducted by the Transferred Entities on June 10,2026, and in respect to (a) Automotive Czech, the business conducted by the KOP Enterprise and (b) DUS Operating Inc., the business conducted by the U.S. Enterprise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase Price and Consideration: </i>As consideration for such purchase, <span id="xdx_901_ecustom--PurchasePriceAndConsiderationDescription_c20260610__20260610__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2o1FIeEzA66" title="Purchase price and consideration description">the Company agreed to pay the Seller (or one or more of its designated other Sellers or Affiliates) at least two (2) Business Days prior to the date of Closing (“Closing Date”) an amount equal to: (i) $30,000,000 (the “Purchase Price”) plus (ii) $800,000 in respect of deferred revenue of the Business Entities (such $800,000 representing an agreed upon fixed credit for the deferred revenue, regardless of the actual amount of the deferred revenue), minus (iii) any Income Tax obligations of the Transferred Entities net of any Income Tax receivables, minus (iv) Indebtedness of the Transferred Entities as of the closing (such final amount, the “Closing Purchase Price”). The Purchase Price will be allocated among the Transferred Entities and/or business units as set forth in the Purchase Agreement. To the extent relevant under applicable Tax Law, the Purchase Price associated with each Transferred Entity and/or business unit will be further allocated among the assets of such Transferred Entities in a manner consistent with Section 1060 of the Internal Revenue Code.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On August 6, 2026, the Company entered into an Escrow and Closing Agreement pursuant to which the parties acknowledged and agreed that all conditions to the closing of the transactions per the Purchase Agreement had been satisfied. (<i>see Note 11. Subsequent Events</i>)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Commitment Letter for Credit Facility</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2026, the Company entered into a commitment letter with a national financial institution providing for a senior secured credit facility of Aspire in an aggregate principal amount of up to $<span id="xdx_908_eus-gaap--LineOfCreditFacilityPeriodicPaymentPrincipal_c20260501__20260531__us-gaap--CreditFacilityAxis__custom--AspireCreditFacilityMember_zVwOaS9Dddk9" title="Credit facility principal amount">22,500,000</span> (the “Aspire Credit Facility”). Aspire intends to use the proceeds of the Aspire Credit Facility, if consummated, to finance the acquisition of <span id="xdx_909_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_pid_dp_uPure_c20260531__us-gaap--CreditFacilityAxis__custom--AspireCreditFacilityMember__us-gaap--BusinessAcquisitionAxis__custom--DriverControlsSystemsBusinessUnitMember_zuqU1tWKC4gb" title="Acquisition percentage">100</span>% of Dura Driver Control Systems (“DCS”). The Company does not anticipate procuring any new equity raise to consummate the purchase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Aspire Credit Facility is expected to consist of a senior secured five-year term loan, at an interest rate equal to 325 basis points above the one-month term Secured Overnight Financing Rate. The final terms of the Aspire Credit Facility, including the senior secured term loan, will be subject to execution of definitive credit documentation and the satisfaction of customary closing conditions. During the three and six months ended June 30, 2026, $<span id="xdx_906_ecustom--UpfrontFeePaid_c20260401__20260630_zwJfoPzVfsT7" title="Upfront fee paid"><span id="xdx_90E_ecustom--UpfrontFeePaid_c20260101__20260630_zxhiPTAHaM9f" title="Upfront fee paid">75,000</span></span> of upfront fee paid to the financial institution is included in deferred financing cost on the unaudited condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal Proceedings</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is and may be subject to various claims, lawsuits and proceedings in the ordinary course of the Company’s business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, in the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected individually or in the aggregate, to result in a material, adverse effect on the Company’s financial condition, results of operations or cash flows. However, it is possible that the Company’s results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal Claim</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--LossContingencyDamagesSought_c20260430__20260430_zhLVwrNoXkq" title="Loss contingency, damages sought">In April 2026, Srirama Associates, LLC filed a lawsuit in the Superior Court of the State of Delaware alleging breach of contract in connection with the modified Promissory Note Fee Agreement. The complaint sought approximately $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_c20260430__20260430_zWyJ2S3qpXa9" title="Loss contingency, damages sought, value">1,000,000</span> in damages, plus interest and costs. The Company disputed the claim and filed a motion to dismiss on May 11, 2026. On June 29, 2026, the claim was dismissed with prejudice by the Superior Court of the State of Delaware and the liability of $<span id="xdx_907_eus-gaap--BankruptcyClaimsAmountOfClaimsFiled_c20260629__20260629_zADCuSfMfTo9" title="Liability claim">1,000,000</span> was written off and included in gain (loss) on extinguishment of debt in the unaudited condensed consolidated statements of operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2441 8199 100000000 In consideration for the execution and delivery of the Second ELOC Agreement, the Company is required to issue common shares to Arena equal to $250,000 divided by the lowest 1-Trading Day VWAP of the common shares of the five (5) Trading Days immediately preceding the effectiveness of the initial registration statement (the “Commitment Fee Shares”), plus $25,000 in common shares for fees associated with the prior ELOC Agreement with the Company, based on a price equal to the lowest 1-Trading Day VWAP of the Common Shares of the five (5) Trading Days immediately preceding the date of execution and delivery of this Agreement. 2510 207 275 865 96527 95662 3628325 0.20 5000000 0.10 the Company agreed to pay the Seller (or one or more of its designated other Sellers or Affiliates) at least two (2) Business Days prior to the date of Closing (“Closing Date”) an amount equal to: (i) $30,000,000 (the “Purchase Price”) plus (ii) $800,000 in respect of deferred revenue of the Business Entities (such $800,000 representing an agreed upon fixed credit for the deferred revenue, regardless of the actual amount of the deferred revenue), minus (iii) any Income Tax obligations of the Transferred Entities net of any Income Tax receivables, minus (iv) Indebtedness of the Transferred Entities as of the closing (such final amount, the “Closing Purchase Price”). The Purchase Price will be allocated among the Transferred Entities and/or business units as set forth in the Purchase Agreement. To the extent relevant under applicable Tax Law, the Purchase Price associated with each Transferred Entity and/or business unit will be further allocated among the assets of such Transferred Entities in a manner consistent with Section 1060 of the Internal Revenue Code. 22500000 1 75000 75000 In April 2026, Srirama Associates, LLC filed a lawsuit in the Superior Court of the State of Delaware alleging breach of contract in connection with the modified Promissory Note Fee Agreement. The complaint sought approximately $1,000,000 in damages, plus interest and costs. The Company disputed the claim and filed a motion to dismiss on May 11, 2026. On June 29, 2026, the claim was dismissed with prejudice by the Superior Court of the State of Delaware and the liability of $1,000,000 was written off and included in gain (loss) on extinguishment of debt in the unaudited condensed consolidated statements of operations. 1000000 1000000 <p id="xdx_80D_ecustom--SecuritiesPurchaseAgreementDisclosureTextBlock_zM7RiezwWobg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. <span id="xdx_829_zPirUoTbs2dd">Securities Purchase Agreement</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>February 2026 Securities Purchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 6, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”), up to <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260206__20260206__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlCUKjphuY0a" title="Shares available for sale">25,000</span> shares (the “Shares”) of the Company’s newly-designated Series A Convertible Preferred Stock, par value $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260206__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWkUZTyP6BS2" title="Preferred stock, par value">0.0001</span> per share (the “Preferred Stock”), which Preferred Stock is convertible into shares of the Company’s common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260206__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z6lv8tWr3Fwk" title="Common stock, par value">0.0001</span> per share (the “Common Stock”) as more fully described in the Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock (the “Certificate of Designation”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Certificate of Designation on February 6, 2026, subject to Stockholder Approval (as defined below), each share of Preferred Stock is convertible at the option of the holder into shares of Common Stock at a conversion price equal to 80% of the lowest closing price of our Common Stock as of the closing of the Principal Market (as such term is defined in the Certificate of Designation) for each of the five (5) Trading Days (as such term is defined in the Certificate of Designation) immediately prior to the date of conversion, or other date of determination (but in no event less than the floor price), subject to certain adjustments as set forth in the Certificate of Designation (the “Conversion Price”). The floor price is equal to 20% of the Minimum Price (as such term is defined by the rules and regulations of The Nasdaq Stock Market LLC under Nasdaq Listing Rule 5635(d)(1)(A)) or such lower amount as permitted, from time to time, by the Principal Market (the “Floor Price”). The number of shares of Common Stock issuable upon conversion of a share of Preferred Stock shall be determined by dividing (x) the stated value of the Preferred Stock to be converted by (y) the Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConvertiblePreferredStockTermsOfConversion_pid_c20260206__20260206__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIWunYPizcR6" title="Preferred stock, conversion term">The shares of Preferred Stock will be convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% of the shares of Common Stock that would be issued and outstanding following such conversion (the “Maximum Percentage”). An Investor may decrease or increase the Maximum Percentage by written notice to the Company from time to time to any other percentage not in excess of 9.99%, provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, provided further that a holder shall not convert any Preferred Stock to the extent that, after giving effect to such conversion, the aggregate number of shares of Common Stock issued or issuable upon conversion of the Preferred Stock would exceed 19.99% of the issued and outstanding shares of the Company’s Common Stock unless and until the Company has obtained the shareholder approval required by Nasdaq Listing Rule 5635(d) (“Shareholder Approval”).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Offering, <span id="xdx_907_eus-gaap--SaleOfStockDescriptionOfTransaction_c20260415__20260415__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1ZGTy4FMHZ7" title="Offering description">the Company filed a proxy statement with the United States Securities and Exchange Commission (the “Commission”) seeking the approval of its stockholders for (i) the transactions contemplated by the Securities Purchase Agreement, (ii) the issuance of the Preferred Stock and the Common Stock issuable upon the conversion of the Preferred Stock, (iii) a reverse stock split of the Company’s Common Stock at a range of one for five (1-for-5) to a maximum of one for five hundred (1-for-500) shares, whether effected in a single transaction or in multiple transactions, and all related amendments to the Company’s certificate of incorporation, and (iv) an amendment to the Company’s certificate of incorporation to effect an increase in the Company’s authorized shares to the extent required to issue the securities. The Company filed the registration statement to issue the shares on February 17, 2026. On February 24, 2026, the SEC notified the Company in writing that there will be no review of the registration statement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company and each Investor entered into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, within fifteen (15) days following the Initial Closing, the Company shall file a resale registration statement on Form S-1 (or Form S-3 if the Company is S-3 eligible) providing for the resale by the Investors of the Registrable Securities (as defined in the Registration Rights Agreement) and to use its best efforts to cause such resale registration statement to be declared effective by the staff of the Commission within forty five (45) days following the Initial Closing, or within sixty five (65) days in the event of a review by the Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Securities Purchase Agreement, the Investors have the right to appoint one (1) director to our Board of Directors. The Securities Purchase Agreement and Registration Rights Agreement contain certain representations and warranties, covenants and indemnities customary for similar transactions. The representations, warranties and covenants contained in the Securities Purchase Agreement and Registration Rights Agreement were made solely for the benefit of the parties to the Securities Purchase Agreement and Registration Rights Agreement and may be subject to limitations agreed upon by the contracting parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Convertible Preferred Stock Issuance</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the February 2026 Securities Purchase Agreement, on February 2, 2026, the Company filed the certificate of designation (the “Certificate of designation”) with The Delaware Secretary of State designating, <span id="xdx_90A_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20260202__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zxF9EF8Q1fP" title="Temporary equity shares authorized">25,000</span> shares of authorized and unissued preferred stock as Series A Convertible Preferred Stock. At the close of the first tranche, the company recorded $<span id="xdx_901_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20260202__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zUWxBhSTrao4" title="Temporary equity carrying amount">9,894,920</span> as Series A Convertible Preferred Stock, representing total issuance of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260202__20260202__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYnchxAVTV5b" title="Total issuance of shares value">13,749,980</span> net of related costs of $<span id="xdx_90D_eus-gaap--PaymentsOfStockIssuanceCosts_c20260202__20260202__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zclIGJntmfk9" title="Issuance of shares related costs">3,855,060</span>. On February 6, 2026, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260206__20260206__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ziQkzS8MusGc" title="Shares issued">13,750</span> shares of Series A Convertible Preferred Stock were issued at the close of the first tranche.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2026, the Company filed the further amendment to the Certificate of designation with the Delaware Secretary of State designating, <span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20260413__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z2s2golRmTD8" title="Temporary equity shares authorized">30,000</span> shares of the authorized and unissued preferred stock as Series A Convertible Preferred Stock. On April 13, 2026, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260413__20260413__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zsgZpmip0Yij" title="Shares issued">12,500</span> additional shares were issued at the close of tranche 2 of the February 2026 Securities Purchase Agreement and the Company recorded $<span id="xdx_908_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20260413__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z0OvwCIklz21" title="Temporary equity carrying amount">9,000,000</span> as Series A Convertible Preferred Stock, representing total issuance of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260413__20260413__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zM4YQgslxf86" title="Total issuance of shares value">10,000,000</span> net of related costs of $<span id="xdx_90A_eus-gaap--PaymentsOfStockIssuanceCosts_c20260413__20260413__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8c6PRSxhKli" title="Issuance of shares related costs">1,000,000</span>. The Certificate of Designation sets forth the rights, preferences and limitations of the shares of Preferred Stock. Terms not otherwise defined in this item shall have the meanings given in the Certificate of Designation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended June 30, 2026, holders of the preferred stock converted <span id="xdx_909_ecustom--ConversionOfSeriesConvertiblePreferredStockToCommonStockShares_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUB6SH29XQKe" title="Preferred Stock shares conversion">9,200</span> shares of Series A Convertible Preferred Stock into <span id="xdx_907_ecustom--ConversionOfSeriesConvertiblePreferredStockToCommonStockShares_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFyayIQEW4Fe" title="Preferred Stock shares conversion">1,122,764</span>, shares of common stock. The Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zmTc00eJFey3" title="Preferred stock, shares outstanding">17,050</span> shares of Series A Convertible Preferred Stock outstanding at June 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the terms of the Preferred Stock:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Certificate of Designation, each share of Preferred Stock, subject to the Stockholder Approval (as defined in the Certificate of Designation), is convertible at the option of the holder into shares of common stock at a conversion price equal to 80% of the lowest closing price of our Common Stock as of the closing of the Principal Market (as such term is defined in the Certificate of Designation) for each of the five (5) Trading Days (as such term is defined in the Certificate of Designation) immediately prior to the date of conversion, or other date of determination (but in no event less than the floor price), subject to certain adjustments as set forth in the Certificate of Designation (the “Conversion Price”). The floor price is equal to 20% of the Minimum Price (as such term is defined by the rules and regulations of the Nasdaq Stock Market LLC, Rule 5635(d)(1)(A)) (or such lower amount as permitted, from time to time, by the Principal Market (the “Floor Price”). The number of shares of common stock issuable upon conversion of a share of Preferred Stock shall be determined by dividing (x) the stated value of the Preferred Stock to be converted by (y) the Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConvertiblePreferredStockTermsOfConversion_pid_c20260202__20260202__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuw3ulJKFyg9" title="Preferred stock, conversion term">The shares of Preferred Stock will be convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% (the “Maximum Percentage”) of the shares of common stock that would be issued and outstanding following such conversion. An Investor may decrease or increase the Maximum Percentage by written notice to the Company from time to time to any other percentage not in excess of 9.99%, provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, provided further that a holder shall not convert any Preferred Stock to the extent that, after giving effect to such conversion, the aggregate number of shares of common stock issued or issuable upon conversion of the Preferred Stock would exceed 19.99% of the issued and outstanding shares of the Company’s common stock unless and until the Company has obtained the shareholder approval required by Nasdaq Listing Rule 5635(d).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ranking</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A shall rank (i) senior to all of the common stock; (ii) senior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms junior to any Series A (“Junior Securities”); (iii) on parity with any class or series of capital stock of the Corporation created specifically ranking by its terms on parity with the Preferred Stock (“Parity Securities”); and (iv) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking by its terms senior to any Series A (“Senior Securities”), in each case, as to dividends or distributions of assets upon liquidation, dissolution, winding up of the Corporation, whether voluntarily or involuntarily. Subject to any superior liquidation rights of the holders of any Senior Securities of the Corporation and the rights of the Corporation’s existing and future creditors, upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “Liquidation”), each Holder shall be entitled to be paid out of the assets of the Corporation legally available for distribution to stockholders, prior and in preference to any distribution of any of the assets or surplus funds of the Corporation to the holders of the Common Stock and Junior Securities and pari passu with any distribution to the holders of Parity Securities, an amount equal to the Stated Value for each share of Series A held by such Holder plus an amount equal to any accrued and unpaid dividends thereon, and thereafter the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series A were fully converted (disregarding for such purposes any conversion limitations hereunder) to common stock which amounts shall be paid pari passu with all holders of common stock. The Corporation shall mail written notice of any such Liquidation, not less than sixty (60) days prior to the payment date stated therein, to each Holder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Price Protection</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except for any Exempt Issuance, in the event the Corporation issues or sells any securities including options or convertible securities (or amends any outstanding securities of the Company), at an effective price of, or with an exercise or conversion price of less than the conversion price, then upon such issuance or sale, the conversion price shall be reduced to the lesser of (i) the Floor Price; or (ii) the sale price or the exercise or conversion price of the securities issued or sold. In case any shares of common stock, convertible securities or options are issued in connection with the issue or sale of other securities of the Company, together comprising one integrated transaction, each share of common stock underlying any such convertible securities or options shall be deemed to be one additional share of common stock for the purposes of determining the effective price of the non-Exempt Issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Participation Rights</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to certain terms and conditions in the Certificate of Designation, until the six (6) month anniversary of the issuance of the Series A to the Holder, upon any subsequent financing, the Holders of the outstanding Series A shall have the right to participate in an amount equal to an aggregate of 30% of the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 25000 0.0001 0.0001 The shares of Preferred Stock will be convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% of the shares of Common Stock that would be issued and outstanding following such conversion (the “Maximum Percentage”). An Investor may decrease or increase the Maximum Percentage by written notice to the Company from time to time to any other percentage not in excess of 9.99%, provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, provided further that a holder shall not convert any Preferred Stock to the extent that, after giving effect to such conversion, the aggregate number of shares of Common Stock issued or issuable upon conversion of the Preferred Stock would exceed 19.99% of the issued and outstanding shares of the Company’s Common Stock unless and until the Company has obtained the shareholder approval required by Nasdaq Listing Rule 5635(d) (“Shareholder Approval”). the Company filed a proxy statement with the United States Securities and Exchange Commission (the “Commission”) seeking the approval of its stockholders for (i) the transactions contemplated by the Securities Purchase Agreement, (ii) the issuance of the Preferred Stock and the Common Stock issuable upon the conversion of the Preferred Stock, (iii) a reverse stock split of the Company’s Common Stock at a range of one for five (1-for-5) to a maximum of one for five hundred (1-for-500) shares, whether effected in a single transaction or in multiple transactions, and all related amendments to the Company’s certificate of incorporation, and (iv) an amendment to the Company’s certificate of incorporation to effect an increase in the Company’s authorized shares to the extent required to issue the securities. The Company filed the registration statement to issue the shares on February 17, 2026. On February 24, 2026, the SEC notified the Company in writing that there will be no review of the registration statement. 25000 9894920 13749980 3855060 13750 30000 12500 9000000 10000000 1000000 9200 1122764 17050 The shares of Preferred Stock will be convertible immediately upon issuance, at the option of the holder, at the Conversion Price, subject to a conversion cap that limits the conversion of the Preferred Stock such that an Investor may not beneficially own more than 4.99% (the “Maximum Percentage”) of the shares of common stock that would be issued and outstanding following such conversion. An Investor may decrease or increase the Maximum Percentage by written notice to the Company from time to time to any other percentage not in excess of 9.99%, provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, provided further that a holder shall not convert any Preferred Stock to the extent that, after giving effect to such conversion, the aggregate number of shares of common stock issued or issuable upon conversion of the Preferred Stock would exceed 19.99% of the issued and outstanding shares of the Company’s common stock unless and until the Company has obtained the shareholder approval required by Nasdaq Listing Rule 5635(d). <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLbKCFIyzMh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. <span id="xdx_827_zKGjHXCRScoi">Stockholders’ equity (deficit)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b>—The Company is authorized to issue <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630_zVxj3ljka9cb">10,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Preferred Stock with a par value of $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260630_zpugLQjO4Ka3">0.0001</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and with such designations, voting and other rights and preferences as may be determined from time to time by the Board. At June 30, 2026 and December 31, 2025, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zpB03cEs01T5">30,000</span> and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zV2vQBjd8kS1">0</span>, respectively, were designated as Series A Convertible Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Convertible Preferred Stock</b>—The Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zxrZ1HuMjjza" title="Preferred stock, shares authorized">30,000</span> shares of Series A Convertible Preferred Stock with a par value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zlCpyr8AgQuk" title="Preferred stock, par value">0.0001</span> per share and with such designations, voting and other rights and preferences as may be determined from time to time by the Board. At June 30, 2026 and December 31, 2025, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zsmWsIEigsw6" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zRELh32Vep1b" title="Preferred stock, shares outstanding">17,050</span></span> and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z8xWO9fuCuwd" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z0lfDklR7nV1" title="Preferred stock, shares outstanding">0</span></span> shares of Series A Convertible Preferred Stock issued or outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b>— The Company is authorized to issue <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20260630_zgICPkqrJvT6" title="Common stock, shares authorized">490,000,000</span> shares of Common Stock with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260630_zRRhW7Dyyfv6" title="Common stock, par value">0.0001</span> per share. As of June 30, 2026, and December 31, 2025, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20260630_z4r3H9Nk0qp9" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20260630_zWPq7DoV1Ds6" title="Common stock, shares outstanding">1,295,234</span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_zhwhkxCoe2pi" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zSx0PlUIpyWj" title="Common stock, shares outstanding">117,780</span></span> shares of common stock issued and outstanding, respectively, after giving effects to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>PowerUp Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the PowerUp IPO, PowerUp issued warrants to third-party investors where <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zLl4aNZT5RT7" title="Warrants purchase">1,200</span> warrant entitles the holder to purchase one share of the Company’s Class A common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zQKT1DcgZF7i" title="Exercise price of warrants">13,800</span> per share (the “Public Warrants”) after giving effect to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>). Simultaneously with the closing of the IPO, PowerUp completed the private sale of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_zPH3lYcRdAz2" title="Exercise price of warrants">8,199</span> warrants (the “Private Placement Warrants”), after giving effect to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>), where each warrant allows the holder to purchase one share of the Company’s Common Stock at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zJVZ94gkhRA" title="Exercise price of warrants">13,800</span> per share, after giving effect to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>)). At June 30, 2026, there are <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zMnHzKytka6l" title="Warrants outstanding">14,374,696</span> Public Warrants and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_zA7dxnnbO6Va">8,199</span> Private Placement Warrants after giving effects to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2025, there are <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zs7oaSlEY3wh">14,374,969</span> Public Warrants and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_zXoigQb74Tpj">8,199</span> Private Placement Warrants outstanding after giving effects to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Public Warrants became exercisable <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtD_c20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zvNFVDVpHhNa" title="Public warrant exercisable term">30</span> days after the consummation of the Reverse Recapitalization.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the warrants becoming exercisable, the Company may redeem the warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● in whole and not in part;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● at a redemption price of $<span id="xdx_905_ecustom--ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_pid_c20260101__20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zhTMz3N5n6fk" title="Redemption price per public warrant">12</span> per warrant;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● upon not less than <span id="xdx_900_ecustom--RedemptionPeriod_dtD_uInteger_c20260101__20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_z6mV5nO0Dxg4" title="Redemption period">30</span> days’ prior written notice of redemption, to each warrant holder; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and only if, the reported last sale price of the Company’s Common Stock equals or exceeds $<span id="xdx_900_ecustom--WarrantRedemptionConditionMinimumSharePrice_pid_c20260101__20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zjhx2tWou8d1" title="Warrant redemption condition minimum share price">21,600</span> per share (as adjusted for share subdivisions, share consolidations, share capitalizations, rights issuances, reorganizations, recapitalizations and the like) for any <span id="xdx_903_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_dtD_c20260101__20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrr1f1KRaFwc" title="Threshold trading days for redemption of public warrants">20</span> trading days within a <span id="xdx_90F_ecustom--ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_uInteger_c20260101__20260630__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zrwCBmphNX2i" title="Threshold consecutive trading days for redemption of public warrants">30</span>-trading day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the IPO, except that the Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable, or saleable until 30 days after the completion of a Reverse Recapitalization, subject to certain limited exceptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined that Public Warrants and the Private Placement Warrants issued in connection with its IPO in February 2022 are subject to treatment as equity. Upon the closing of the Reverse Recapitalization, in accordance with the guidance contained in ASC 815, the warrants continue to be classified as equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock based compensation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 29, 2024, Aspire Biopharma, Inc. entered into a Corporate Advisory Agreement with an advisory firm, pursuant to which the advisory firm will receive <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20240229__20240229__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zetzD3gdumf8" title="Shares outstanding percentage">6</span>% of the amount of shares outstanding after the close of the Reverse Recapitalization as compensation for advisory services to support the Company’s efforts related to the Reverse Recapitalization. On January 3, 2025, the agreed upon compensation was reduced to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20250103__20250103__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zvrytRx46Dn8" title="Shares outstanding percentage">4.75</span>% of the amount of shares outstanding after the close of the Reverse Recapitalization (<i>see Note 3. Reverse Recapitalization</i>). In February 2025, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zMUlSpgXiGLl" title="Shares issued to affiliated company">1,385</span> shares of the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250201__20250228__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zmkokUclRc6j" title="Business combination shares">29,167</span> Reverse Recapitalization shares after giving effects to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>) were issued to the affiliated company under this agreement. The issuance of these shares to the service advisors is subject to ASC 718. Under ASC 718, compensation associated with equity-classified awards is measured at fair value upon the grant date. The shares were granted subject to a performance condition (i.e., the occurrence of a Reverse Recapitalization).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense which is included in general and administrative expenses on the unaudited condensed consolidated statement of operations was $<span id="xdx_903_eus-gaap--GeneralAndAdministrativeExpense_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zmjiS7XbtTn8" title="General and administrative expenses"><span id="xdx_90C_eus-gaap--GeneralAndAdministrativeExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zf6hRffnsmIh" title="General and administrative expenses">157,000</span></span> for both the three and six months ended June 30, 2026, respectively. Upon consummation of the Reverse Recapitalization stock-based compensation was $<span id="xdx_903_eus-gaap--GeneralAndAdministrativeExpense_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zNuIWHbESo2i" title="General and administrative expenses">0</span> and <span id="xdx_908_eus-gaap--GeneralAndAdministrativeExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--CorporateAdvisoryAgreementMember_zFa2CtOVxvDe" title="General and administrative expenses">14,131,250</span> for the three and six months ended June 30, 2025, respectively, based on the grant date fair value per share. The fair value was determined by applying a 15% discount for lack of marketability to the market price of the shares on date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Aspire Biopharma Inc. warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, Aspire Biopharma, Inc. issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AspireBiopharmaWarrantsMember_zYGOGoKko3K2" title="Number of warrants issued">44,000,000</span> warrants at a per share price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AspireBiopharmaWarrantsMember_zgnWbH05Gcdj" title="Exercise price of warrants">0.40</span>. As of December 31, 2024, there were <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AspireBiopharmaWarrantsMember_zHaKN0wIP422" title="Warrants outstanding">91,500,000</span> warrants outstanding and all were fully vested. On January 21, 2025, the <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250121__us-gaap--StatementEquityComponentsAxis__custom--AspireBiopharmaWarrantsMember_ziRdua9rAHVc" title="Warrants outstanding">91,500,000</span> warrants were converted into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20250121__20250121__us-gaap--StatementEquityComponentsAxis__custom--AspireBiopharmaWarrantsMember_zKhImm0eHUJ1" title="Common stock issued upon warrant conversion">91,500,000</span> shares of Aspire Biopharma Inc. common stock, on the Reverse Recapitalization date, and subsequently converted into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20260116__20260116__us-gaap--StatementEquityComponentsAxis__custom--AspireBiopharmaWarrantsMember_zXxCB5cnXhqj" title="Common stock issued upon warrant conversion">4,780</span> shares of common stock of the Company after giving effects to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Share issuances</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2025, in connection with the Settlement Agreement, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250428__20250428__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zArdO3cqU7F9" title="Number of shares issued">521</span> shares of common stock after giving effect to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i> to Blackstone Capital Advisors, Inc. or its designees. (<i>See Note 5. Convertible Notes</i>)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2025, a total value of $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zhMo47cj4fy4" title="Convertible notes amount converted">9,523,683</span> of Convertible Notes were converted into <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_z13k9BAKhJDj" title="Shares issued upon note conversion">73,998</span> shares of common stock of the Company after giving effects to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>). The remaining debt of $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zMskW2OVv9De" title="Remaining debt converted into common stock, value">163,817</span> was converted into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zH1U0GYftG8k" title="Remaining debt converted into common stock, shares">1,625</span> shares of common stock in January 2026 after giving effect to the Second Reverse Split (<i>see Note 1. Description of Business and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As stated in <i>Note 6. Commitments and Contingencies</i>, In January 2026, the Company issued <span id="xdx_90E_ecustom--AdditionalPaymentOfCommitmentFeeShares_c20260101__20260131__dei--LegalEntityAxis__custom--ArenaBusinessSolutionsGlobalSPCIILtdMember_zuJ8M0cb8NM2" title="Additional payment of commitment fee shares">207</span> true up shares to Arena after giving effect to the Second Reverse Split (<i>see Note 1. Description of Business and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As stated in <i>Note 5. Convertible Notes</i>, The Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zSIoRCAvQNy" title="Number of shares issued">26,333</span> shares of common stock as incentive to the Investors for entering into the January 2026 Share Purchase Agreement after giving effect to the Second Reverse Split (<i>see Note 1. Business Description and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 7, 2026, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260407__20260407__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zy2GEJTm2ewg" title="Number of shares issued">5,000</span> shares of common stock, after giving effect to the Second Reverse Split (<i>see Note 1. Business Description and Organization</i>), to a consultant pursuant to a consulting agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exchange Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2026, the Company entered into Exchange Agreements (the “Exchange Agreements”) with certain holders of the Company’s subscription agreement loans (the “Holders”) to exchange approximately $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20260101__20260101__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember_zmoPs4Mr0gd3" title="Debt conversion amount">1,750,000</span> in debt for shares (the “Exchange Shares”) of the Company’s common stock (the “Exchange”) (<i>see Note 4. Related Party Transactions</i>). The debt was incurred by the Company’s predecessor, PowerUp pursuant to subscription agreements dated March 5, 2024, and May 9, 2024. The Holders were Sponsors of PowerUp’s initial public offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Exchange Agreements, the Holders may, in their discretion, submit a notice of exchange setting forth the Exchange Amount, the Exchange Shares, and the applicable Exchange Price. Within one business day of receipt of an Exchange Notice, the Company will issue to such Holder the number of Exchange Shares equal to the Exchange Amount divided by the Exchange Price, and such Exchange Amount shall be deducted from the Outstanding Balance. Each Holder may submit up to four (4) Exchange Notices, but each Exchange Notice may not exchange more than thirty percent (30%) of the applicable Holder’s Outstanding Balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, <span id="xdx_908_eus-gaap--DebtConversionDescription_pid_c20260101__20260101__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember_zlbCf9nXHeW" title="Exchange description">upon a financing in excess of $3,000,000 (a “Financing”), the Company may repay part or all of any Holder’s Outstanding Balance. Upon a Financing, a Holder may elect to receive cash proceeds from any Financing in an amount equal to twenty five percent (25%) of such Holder’s Outstanding Balance, to be applied to such Holder’s Outstanding Balance. If a Holder elects to require any part of its Outstanding Balance to be repaid from the proceeds of a Financing, it can elect to receive up to 33.33% of the aggregate proceeds of such Financing.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2026, pursuant to the Exchange Agreements, the Subscription Agreement Loan balances along with applicable interest were converted into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember_zQml4njSdJEi" title="Number of shares issued upon debt conversion">21,525</span> shares of common stock of the Company after giving effect to the Reverse Splits (<i>see Note 1. Description of Business and Organization</i>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 0.0001 30000 0 30000 0.0001 17050 17050 0 0 490000000 0.0001 1295234 1295234 117780 117780 1200 13800 8199 13800 14374696 8199 14374969 8199 P30D 12 P30D 21600 P20D 30 0.06 0.0475 1385 29167 157000 157000 0 14131250 44000000 0.40 91500000 91500000 91500000 4780 521 9523683 73998 163817 1625 207 26333 5000 1750000 upon a financing in excess of $3,000,000 (a “Financing”), the Company may repay part or all of any Holder’s Outstanding Balance. Upon a Financing, a Holder may elect to receive cash proceeds from any Financing in an amount equal to twenty five percent (25%) of such Holder’s Outstanding Balance, to be applied to such Holder’s Outstanding Balance. If a Holder elects to require any part of its Outstanding Balance to be repaid from the proceeds of a Financing, it can elect to receive up to 33.33% of the aggregate proceeds of such Financing. 21525 <p id="xdx_80F_eus-gaap--FairValueDisclosuresTextBlock_zi9qL3h1xFa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_824_zi0TXnkjfAn6">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zTvgpCgpz6Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s fair value hierarchy assets and liabilities that are measured at fair value on a recurring basis at June 30, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_ziH6iQaaS1td" style="display: none">Schedule of Assets and Liabilities That are Measured at Fair Value On a Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Balance Sheet Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zentxbqXLbe1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Quoted Prices in Active Markets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkRVlZAxXQdc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Observable Inputs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpPtVC35xc1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Unobservable Inputs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Level 1)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Level 2)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Level 3)</td><td> </td></tr> <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLl6CLnmAa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashEquivalentsAtCarryingValue_iI_zh7HpgHCQED7" style="vertical-align: bottom; background-color: White"> <td style="width: 20%; text-align: left">Money market funds</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,652,779</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_znSd3J5bqUX1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ForwardPurchaseAgreementLiability_iI_zKvHVGNGgTgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forward purchase agreement liability</td><td> </td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">96,252</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">December 31, 2025</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Balance Sheet Classification</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6y6cuPvTqih" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Quoted Prices in Active Markets</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zf8eGKPEtM8f" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Observable Inputs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjryi7Pmwor9" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Unobservable Inputs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zGFAyrnejrX6" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">      </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleDebtFairValueDisclosures_i01I_zEchiCmvmud6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Convertible notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,146,236</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ForwardPurchaseAgreementLiability_iI_zNaejYO7nnl3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forward purchase agreement liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">95,662</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DerivativeLiabilities_i01I_zMs8sRagJ10g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">40,954</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_i01I_zWToMHgn2654" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1255">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,282,852</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zXTwc21Ekxh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Convertible notes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in <i>Note 5. Convertible Notes</i>, the February 2025 Convertible Debentures are classified and accounted for as a financial liability which is measured at fair value on a recurring basis (one of the instruments is accounted for at fair value on a recurring basis under ASC 480-10, as a derivative instrument under ASC 815).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial liabilities are valued under a Monte Carlo Model. The estimated fair value of the financial liabilities component is determined using Level 3 inputs. Inherent in the pricing models are assumptions related to expected share-price volatility, expected life and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfConvertibleNotesTableTextBlock_zZdIH1LTQnp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant inputs of the models used to value the Company’s February 2025 Convertible Debentures as of December 31, 2025 were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zWVdVwFWerpf" style="display: none">Schedule of Convertible Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Inputs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Term Remaining - Years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2tt4sVJRlEk" style="width: 16%; text-align: right" title="Term Remaining">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zV3OCBjxv9p3" style="text-align: right" title="Share Price">0.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zOaefcqbBKPh" title="Convertible notes measurement input">12.49</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AE_zGep1MVt27e1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfFairValueOfConvertibleNotesTableTextBlock_zCHOdTch1Kca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the February 2025 Convertible Notes measured using Level 3 inputs is summarized as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_z7N8x0yQx9C4" style="display: none">Schedule of Fair Value of the Convertible Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_4B9_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z7QY7RllQmu" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_436_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iS_zfj0QZY1CjUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at, December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,146,236</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_431_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iS_zKdebB6n8zbl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Convertible notes, beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,146,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PaidInKindInterest_z4qjPo5YKH3e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Paid in kind interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ChangeInFairValueConvertibleNotes_zSNRtFYazGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(211,443</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--RepaymentsOfConvertibleDebt_iN_di_z4gyUTuLXTFc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Repayment of Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(943,801</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_431_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iE_z5fVIyYUe2oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_435_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iE_z8h2tJvnQ8ej" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Convertible notes, ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zHWto6rX0RDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Forward purchase agreement liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in <i>Note </i>6<i>. Commitment and Contingencies</i>, the forward purchase agreement liabilities are classified and accounted for as financial liabilities which are measured at fair value on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The forward purchase agreements liabilities are valued under a Probability Weighted Expected Return Model (“PWERM”) which fair values reportable capital investment and uses a Black Scholes Model that fair values the conversion features within the convertible debt. The PWERM is a multistep process in which value is estimated based on the probability-weighted present value of various future outcomes. The estimated fair value of the forward purchase agreements liabilities are determined using Level 3 inputs. Inherent in the pricing models are assumptions related to expected share-price volatility, expected life and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_ecustom--FairValueAssetsAndLiabilitiesMeasuredOnForwardPurchaseAgreementLiabilitiesValuationTechniquesTableTextBlock_zEaDZc7VN3b2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant inputs of the models used to value the forward purchase agreement liabilities as of June 30, 2026 and December 31, 2025 were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zzBFiZgqIWtg" style="display: none">Schedule of Models Used in Forward Purchase Agreements Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Share Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXsaSybkbMGj" title="Derivative liability measurement input">5.34</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zcayLojmS4Qc" title="Derivative liability measurement input">5.28</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zprTAQqT6Zce" title="Derivative liability measurement input">3.87</span>% - <span id="xdx_90C_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zLYJ8c15evgg" title="Derivative liability measurement input">4.18</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zxppbGLhKYH3" title="Derivative liability measurement input">3.48</span>% - <span id="xdx_90B_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z1qnJIBGmaO5" title="Derivative liability measurement input">3.59</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Likelihood of a call</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MinimumMember_zOhoDCZKazIe" title="Derivative liability measurement input">10</span>% -<span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MaximumMember_zFpRK4PYmdPa" title="Derivative liability measurement input">20</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MinimumMember_zLJnqzTBWDwj" title="Derivative liability measurement input">10</span>% -<span id="xdx_90D_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MaximumMember_zb2tIJln2jp6" title="Derivative liability measurement input">20</span>%</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zd8y3bHBfOSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfFairValueOfForwardPurchaseAgreementLiabilitiesTableTextBlock_zU5j5PFfl7u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the forward purchase agreement liabilities measured using Level 3 inputs is summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_z0Nl79cwTyM9" style="display: none">Schedule of Fair Value Forward Purchase Agreement Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td><td id="xdx_4BA_zqsQtrR6cHt1" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr id="xdx_435_c20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iS_zlIvliSZOkAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">95,662</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueAdjustment_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZWC0ULxacCg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">590</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_433_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iS_zzLNooegcUR7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,252</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iS_zOBjkjJ4i9ub" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,252</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueAdjustment_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNs2O1EuS8d5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">275</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iE_zjIY3IgbfgYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iE_zGqZJvDErmo3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zchug6AXfsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative liability</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in <i>Note 5. Convertible Notes</i>, the Company accounted for the August 2025 Notes under ASC 470 and ASC 815 and concluded that bifurcation of multiple embedded features was necessary under ASC 815-15-25-1. As a result, the Company separately accounted for it as a single compound derivative. The initial fair value of the derivative liability at issuance was $<span id="xdx_905_ecustom--InitialRecognitionDerivativeLiability_c20260101__20260630_z13HmmJKb6uk" title="Initial recognition derivative liability">4,101,583</span> and estimated using a Monte Carlo Model. In January 2026, the remaining balance of $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ3feWYf8Jl2" title="Remaining debt converted into common stock, value">163,817</span> of the convertible notes was converted into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20260101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfO4NMOvrtef" title="Remaining debt converted into common stock, shares">1,625</span> shares of common stock after giving effects to the Reverse Splits (<i>see Note 1. Business Description and Organization</i>). For the three and six months ended June 30, 2026, change in fair value of the derivative liability of $<span id="xdx_900_ecustom--ChangeInFairValueDerivativeLiability_c20260401__20260630_zYdFVwzeYjVe" title="Change in fair value derivative liability">0</span> and $<span id="xdx_902_ecustom--ChangeInFairValueDerivativeLiability_c20260101__20260630_z3auY9xHafpb" title="Change in fair value derivative liability">40,954</span> was recorded as an income on the unaudited condensed consolidated statements of operations, respectively. At June 30, 2026 and December 31, 2025, the fair value of the derivative of $<span id="xdx_90F_eus-gaap--DerivativeLiabilitiesCurrent_iI_dxL_c20260630_zizFUzgVtnl9" title="Fair value derivative liabilities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1330">0</span></span> and $<span id="xdx_90B_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20251231_zgMKu7yyzsm2" title="Fair value derivative liabilities">40,954</span>, respectively, was included in derivative liability on the accompanying unaudited condensed unaudited condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCoYZGls8cPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the derivative liability measured using Level 3 inputs is summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zdmnlRMUb6z5" style="display: none">Summary of Change in Fair Value of Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_4B3_us-gaap--FairValueByLiabilityClassAxis_us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_ziW4dbtMnObe" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_435_c20260101__20260331_eus-gaap--DerivativeLiabilitiesCurrent_iS_zyJEwVe6hTd3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">40,954</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ChangeInFairValueDerivativeLiability_iN_di_zB1PvikT4kH3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40,954</td><td style="text-align: left">)</td></tr> <tr id="xdx_43E_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iS_zSuuKOqimoJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iS_zmSQ0rA1i9Xe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Derivative liability, beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ChangeInFairValueDerivativeLiability_iN_di_zRzQKYQy5qZ" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43F_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iE_z6o4K2xJEBQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_438_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iE_zgSFaFjTO3hi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Derivative liability, ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zlLpfVRI12M9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zY896AbDbUz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant inputs of the models used to value the Company’s derivative liability as of December 31, 2025, were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zXJxQzC033U" style="display: none">Schedule of Key Inputs of Models Used to Value Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; width: 82%; font-weight: bold">Inputs</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: center">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Term Remaining - Years</td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zAAQFKQPRJv7" title="Derivative liability measurement input">0.14</span> - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zkb34hjthk8" title="Derivative liability measurement input">0.39</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share Price</td><td> </td> <td style="text-align: right">$<span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_znpelhxJUEzj" title="Derivative liability measurement input">0.10</span>- $<span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zh3GJHAW71e2" title="Derivative liability measurement input">0.42</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z5l8ltqGaLch" title="Derivative liability measurement input">3.52</span>% - <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3AnucQ16856" title="Derivative liability measurement input">3.92</span>%</td></tr> </table> <p id="xdx_8AF_zO3w8Dnn6TYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zTvgpCgpz6Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Company’s fair value hierarchy assets and liabilities that are measured at fair value on a recurring basis at June 30, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_ziH6iQaaS1td" style="display: none">Schedule of Assets and Liabilities That are Measured at Fair Value On a Recurring Basis</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold">June 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Balance Sheet Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zentxbqXLbe1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Quoted Prices in Active Markets</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkRVlZAxXQdc" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Observable Inputs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpPtVC35xc1" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Unobservable Inputs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Level 1)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Level 2)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Level 3)</td><td> </td></tr> <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zLl6CLnmAa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CashEquivalentsAtCarryingValue_iI_zh7HpgHCQED7" style="vertical-align: bottom; background-color: White"> <td style="width: 20%; text-align: left">Money market funds</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,652,779</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1227">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_znSd3J5bqUX1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ForwardPurchaseAgreementLiability_iI_zKvHVGNGgTgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forward purchase agreement liability</td><td> </td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">96,252</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">December 31, 2025</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Balance Sheet Classification</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6y6cuPvTqih" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Quoted Prices in Active Markets</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zf8eGKPEtM8f" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Observable Inputs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjryi7Pmwor9" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Significant Other Unobservable Inputs</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 1)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 2)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level 3)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zGFAyrnejrX6" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">      </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleDebtFairValueDisclosures_i01I_zEchiCmvmud6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Convertible notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,146,236</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ForwardPurchaseAgreementLiability_iI_zNaejYO7nnl3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forward purchase agreement liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">95,662</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DerivativeLiabilities_i01I_zMs8sRagJ10g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Derivative liability</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">40,954</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_i01I_zWToMHgn2654" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1255">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,282,852</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11652779 96252 1146236 95662 40954 1282852 <p id="xdx_899_ecustom--ScheduleOfConvertibleNotesTableTextBlock_zZdIH1LTQnp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant inputs of the models used to value the Company’s February 2025 Convertible Debentures as of December 31, 2025 were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zWVdVwFWerpf" style="display: none">Schedule of Convertible Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Inputs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Term Remaining - Years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z2tt4sVJRlEk" style="width: 16%; text-align: right" title="Term Remaining">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share Price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zV3OCBjxv9p3" style="text-align: right" title="Share Price">0.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zOaefcqbBKPh" title="Convertible notes measurement input">12.49</span></td><td style="text-align: left">%</td></tr> </table> 0.13 0.13 12.49 <p id="xdx_898_ecustom--ScheduleOfFairValueOfConvertibleNotesTableTextBlock_zCHOdTch1Kca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the February 2025 Convertible Notes measured using Level 3 inputs is summarized as follow:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_z7N8x0yQx9C4" style="display: none">Schedule of Fair Value of the Convertible Notes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_4B9_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z7QY7RllQmu" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_436_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iS_zfj0QZY1CjUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at, December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,146,236</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_431_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iS_zKdebB6n8zbl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Convertible notes, beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,146,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PaidInKindInterest_z4qjPo5YKH3e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Paid in kind interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ChangeInFairValueConvertibleNotes_zSNRtFYazGOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(211,443</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--RepaymentsOfConvertibleDebt_iN_di_z4gyUTuLXTFc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Repayment of Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(943,801</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_431_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iE_z5fVIyYUe2oa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_435_c20260101__20260630_eus-gaap--ConvertibleDebtCurrent_iE_z8h2tJvnQ8ej" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Convertible notes, ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1280">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1146236 1146236 9008 -211443 943801 <p id="xdx_890_ecustom--FairValueAssetsAndLiabilitiesMeasuredOnForwardPurchaseAgreementLiabilitiesValuationTechniquesTableTextBlock_zEaDZc7VN3b2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant inputs of the models used to value the forward purchase agreement liabilities as of June 30, 2026 and December 31, 2025 were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zzBFiZgqIWtg" style="display: none">Schedule of Models Used in Forward Purchase Agreements Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Share Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zXsaSybkbMGj" title="Derivative liability measurement input">5.34</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zcayLojmS4Qc" title="Derivative liability measurement input">5.28</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zprTAQqT6Zce" title="Derivative liability measurement input">3.87</span>% - <span id="xdx_90C_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zLYJ8c15evgg" title="Derivative liability measurement input">4.18</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zxppbGLhKYH3" title="Derivative liability measurement input">3.48</span>% - <span id="xdx_90B_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z1qnJIBGmaO5" title="Derivative liability measurement input">3.59</span>%</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Likelihood of a call</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MinimumMember_zOhoDCZKazIe" title="Derivative liability measurement input">10</span>% -<span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MaximumMember_zFpRK4PYmdPa" title="Derivative liability measurement input">20</span>%</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MinimumMember_zLJnqzTBWDwj" title="Derivative liability measurement input">10</span>% -<span id="xdx_90D_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputLikelihoodMember__srt--RangeAxis__srt--MaximumMember_zb2tIJln2jp6" title="Derivative liability measurement input">20</span>%</span></td><td style="text-align: left"> </td></tr> </table> 5.34 5.28 3.87 4.18 3.48 3.59 10 20 10 20 <p id="xdx_89C_ecustom--ScheduleOfFairValueOfForwardPurchaseAgreementLiabilitiesTableTextBlock_zU5j5PFfl7u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the forward purchase agreement liabilities measured using Level 3 inputs is summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_z0Nl79cwTyM9" style="display: none">Schedule of Fair Value Forward Purchase Agreement Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center"> </td><td id="xdx_4BA_zqsQtrR6cHt1" style="border-bottom: Black 1pt solid; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr id="xdx_435_c20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iS_zlIvliSZOkAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">95,662</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueAdjustment_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZWC0ULxacCg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">590</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_433_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iS_zzLNooegcUR7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,252</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iS_zOBjkjJ4i9ub" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,252</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueAdjustment_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNs2O1EuS8d5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">275</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iE_zjIY3IgbfgYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43E_c20260401__20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_eus-gaap--EquityFairValueDisclosure_iE_zGqZJvDErmo3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">96,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 95662 590 96252 96252 275 96527 96527 4101583 163817 1625 0 40954 40954 <p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCoYZGls8cPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the fair value of the derivative liability measured using Level 3 inputs is summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zdmnlRMUb6z5" style="display: none">Summary of Change in Fair Value of Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_4B3_us-gaap--FairValueByLiabilityClassAxis_us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_ziW4dbtMnObe" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_435_c20260101__20260331_eus-gaap--DerivativeLiabilitiesCurrent_iS_zyJEwVe6hTd3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">40,954</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ChangeInFairValueDerivativeLiability_iN_di_zB1PvikT4kH3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40,954</td><td style="text-align: left">)</td></tr> <tr id="xdx_43E_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iS_zSuuKOqimoJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iS_zmSQ0rA1i9Xe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Derivative liability, beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--ChangeInFairValueDerivativeLiability_iN_di_zRzQKYQy5qZ" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_43F_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iE_z6o4K2xJEBQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_438_c20260401__20260630_eus-gaap--DerivativeLiabilitiesCurrent_iE_zgSFaFjTO3hi" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Derivative liability, ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 40954 40954 <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zY896AbDbUz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant inputs of the models used to value the Company’s derivative liability as of December 31, 2025, were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zXJxQzC033U" style="display: none">Schedule of Key Inputs of Models Used to Value Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; width: 82%; font-weight: bold">Inputs</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 16%; font-weight: bold; text-align: center">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Term Remaining - Years</td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zAAQFKQPRJv7" title="Derivative liability measurement input">0.14</span> - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zkb34hjthk8" title="Derivative liability measurement input">0.39</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share Price</td><td> </td> <td style="text-align: right">$<span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_znpelhxJUEzj" title="Derivative liability measurement input">0.10</span>- $<span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zh3GJHAW71e2" title="Derivative liability measurement input">0.42</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk Free Rate</td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z5l8ltqGaLch" title="Derivative liability measurement input">3.52</span>% - <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z3AnucQ16856" title="Derivative liability measurement input">3.92</span>%</td></tr> </table> 0.14 0.39 0.10 0.42 3.52 3.92 <p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_zLZpz8qGcbna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. <span id="xdx_82B_zl481g5GBsma">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company determines its operating segments in accordance with FASB ASC 280, <i>Segment Reporting</i> (“ASC 280”). ASC 280 defines operating segments as components where discrete financial information is regularly reviewed by the chief operating decision maker (“CODM”), which for the Company is the Chief Executive Officer, to determine resource allocation and assess performance. As such, based on the way the CODM monitors and makes decisions affecting operations, the Company has concluded that it has one operating and reportable segment. The CODM is regularly provided with only the consolidated expenses as noted on the face of the condensed consolidated statements of operations. As the Company has only one operating segment and is managed on a consolidated basis, the measure of profit or loss is consolidated net income or loss. The metrics are used to review operating trends, to perform analytical comparisons between periods and to monitor budget to actual variances. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net loss, which include the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All other segment items included in net loss are reported on the unaudited condensed consolidated statements of operations and described within their respective disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zrNWzDdNsIyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. <span id="xdx_82F_zQoXbcafLqIb">Subsequent Events</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than disclosed below or within these unaudited condensed consolidated financial statements, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Conversion of Preferred Stock and Effects on Stockholders’ Equity</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In July 2026, certain holders of the Series A Convertible Preferred Stock converted <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20260701__20260731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zByJuLm5xmgk" title="Shares converted">850</span> shares at a conversion price of $<span id="xdx_90B_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20260701__20260731__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zfEp48q1D298" title="Conversion price">7.92</span> into <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20260701__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzDuPeuxDPH" title="Share issued on conversion">107,323</span> shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Purchase Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On June 10, 2026, the Company entered into a purchase agreement (“Purchase Agreement”) with FireFish Topco LLC (the “Seller and collectively with its Subsidiaries as identified in the Purchase Agreement, “Sellers”) pursuant to which the Company purchased all of the equity interests in certain of the Seller’s subsidiaries and all of the assets and liabilities of other Business Entities (<i>see Note 6. Commitments and Contingencies</i>) for an amount equal to (i) $<span id="xdx_90A_eus-gaap--ProceedsFromPreviousAcquisition_c20260610__20260610__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zZRJXoaPNsb4" title="Purchase price">30,000,000</span> the Purchase Price plus (ii) $<span id="xdx_903_eus-gaap--DeferredRevenue_iI_c20260610__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znKB8IE73tp2" title="Deferred revenue">800,000</span> in respect of deferred revenue of the Business Entities minus (iii) any income tax liabilities of the Transfer Entities minus (iv) indebtedness of the Transfer Entities and was funded with cash on hand. The closing date of the acquisition was August 6, 2026. (<i>see below Escrow and Closing Agreement and Working Capital Financing: Note Purchase Agreement)</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On August 6, 2026, the Company entered into an Escrow and Closing Agreement (see below) pursuant to which the parties acknowledged and agreed that all conditions to the closing of the transactions per the Purchase Agreement had been satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As a result of the limited time since the acquisition date and the effort required to conform the financial statements to the Company’s practices and policies, the initial accounting for the business combination is incomplete at the time of this filing. As a result, the Company is unable to provide the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Escrow and Closing Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 6, 2026, the Company and FireFish TopCo, LLC (the “Seller”) entered into an Escrow and Closing Agreement (the “Closing Agreement”), pursuant to which the parties acknowledged and agreed that all conditions to the closing of the transactions contemplated by the Purchase Agreement (see <i>Note 6. Commitments and Contingencies</i>) (the “Closing”) had been irrevocably satisfied or irrevocably waived by the party entitled to the benefit thereof, and that all Transaction Documents, certificates and other deliverables required to effect the Closing (collectively, the “Closing Documents”) had been duly executed and irrevocably delivered by the parties and were being held in escrow by the parties (or their respective counsel) pending automatic release as described below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the Closing Agreement, the Closing Documents will be automatically released from escrow without any further action, and the Closing will be deemed to occur automatically and without any further action, immediately upon payment by the Company to the Seller of the Closing Purchase Price in accordance with the closing statement delivered by the Seller to the Company on July 28, 2026 under the Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has agreed to immediately pay the Closing Purchase Price to the Seller upon receipt of funds from its debt financing source (the “Financing”). The Closing Agreement provides that the Financing is not, and was not, a condition to the Closing, that the Seller entered into the Closing Agreement as an accommodation to the Company and without prejudice to the Seller’s rights (including its right to terminate the Purchase Agreement pursuant to Section 9.01(c) or Section 9.01(e) thereof to the extent the Closing does not promptly occur after July 31, 2026), and that the Company will use reasonable best efforts to obtain the Financing so as to enable it to pay the Closing Purchase Price as promptly as possible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Working Capital Financing; Note Purchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2026, the board of directors of the Company (the “Board”) adopted resolutions by written consent authorizing the Company to issue convertible promissory notes (the “Notes”) pursuant to a Convertible Promissory Note Purchase Agreement, dated as of August 6, 2026 (the “Note Purchase Agreement”), by and among the Company and the investors named therein (the “Investors”). Pursuant to the Note Purchase Agreement, the Company will issue and sell to the Investors Notes in an aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvSHReoRo7m4" title="Principal amount">3,750,000</span>, for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNDs36gKOdY6" title="Aggregate purchase price">3,000,000</span>, reflecting an original issue discount of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPs4KrFdScd5" title="Original issue discount">20</span>% (the “Working Capital Transaction”). The proceeds of the Working Capital Transaction are intended to provide additional working capital for the Company’s business and to allow for flexibility to pursue future growth opportunities that the Company may identify in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board ratified, confirmed, consented to and approved the Company’s entry into the Note Purchase Agreement and authorized the Company’s officers to negotiate, execute, deliver and perform the Note Purchase Agreement and related ancillary documents, and to issue the Conversion Shares (as defined below) upon conversion of the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Notes are convertible into shares of the Company’s common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zL6dsv516aYc" title="Common stock, par value">0.0001</span> per share (the “Conversion Shares”), in accordance with the terms of the Notes. The conversion price applicable to the Notes is $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_c20260731__20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpRr04EqN6Fl" title="Conversion price increased">8.00</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">RBW Capital Partners LLC acted as exclusive financial advisor to the Company in connection with the foregoing transactions. Any securities or brokerage services were offered through Dawson James Securities, Inc. RBW received a placement agency fee equal to <span id="xdx_90B_ecustom--PlacementAgencyFeePercentage_pid_dp_uPure_c20260731__20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zH4ohseGoUQj" title="Placement agency fee percentage">8%</span> of the purchase price and non-accountable expenses in the amount of <span id="xdx_901_ecustom--NonAccountableExpensesPercentage_pid_dp_uPure_c20260731__20260731__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNub6nhNFpb5" title="Non accountable expenses percentage">1%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><i>Management Services Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">A Management Services Agreement (the “Agreement”) was entered into on May 10, 2026, between the Company and Lakewood Capital, LLC (“Lakewood”) becoming effective on the closing date of the acquisition of the Drivers Control Systems (“DCS”) business of Dura Automotive (the “Dura Transaction”), August 6, 2026, (the “Effective Date”) (see Escrow and Closing Agreements above). The term of the Agreement is for a period of five years from the Effective Date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">The Management Services to be provided during the term of the Agreement include consultation in connection to the DCS operations with respect to the development and implementation of strategies for improving operating, engineering, manufacturing, marketing, and/or financial performance of the Company, its subsidiaries or affiliates. In consideration of the Management Services, <span id="xdx_901_eus-gaap--ManagementFeeDescription_c20260806__20260806__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zImrofk7jvG7" title="Management fee, description">the Company will pay Lakewood a closing fee of $<span id="xdx_904_ecustom--ClosingFee_c20260806__20260806__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztJWxwttdl95" title="Closing fee">500,000</span> and reimbursement of out-of-pocket expenses not to exceed $200,000 in connection with closing the Dura Transaction. Additionally, the Company will pay Lakewood an aggregate annual management fee equal to 5% of Adjusted EBITDA which means for any period, consolidated earnings before interest, taxes, depreciation, and amortization adjusted to exclude extraordinary items, non-recurring items and other agreed upon items, with an annual cap of $<span id="xdx_908_eus-gaap--ManagementFeeExpense_c20260806__20260806__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zMDyJ2RCZFc2" title="Annual management fee">1,000,000</span> ( the “Annual Management Fee”) with quarterly payments of $250,000 paid (January 1, April 1 and July 1) with final payment on October 1 to be approved by the audit committee of the Board of Directors equal to the difference between 5% Adjusted EBITDA and the $750,000 already paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_904_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20260806__20260806__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zB4Mu7MSK05g" title="Transaction description">In addition, Lakewood will receive 15% of the equity of DCS within 10 days upon the closing of the DCS Transaction, that vests monthly over a two-year period which is currently estimated at approximately $4,500,000 based on the purchase price of $30,000,000. Lakewood also has the opportunity to receive additional liquidity for DCS by receiving a staggered (tranche-based) put option on its 15% of the DCS equity. No exercise of the put may be effected during the first two years after the closing of the Dura Transaction. After the end of year two, Lakewood has the option to sell up to 5% of the DCS equity in any twelve month period subject to a ninety day notice.</span> The put would be payable in cash or Company stock or a combination thereof that would be mutually acceptable to both Lakewood and the Board. The same terms would be applicable to each subsequent year as long as no put exceeds 5% of DCS equity. Valuation of DCS in connection with exercising a put option will be calculated by using a pro-rata share of EBITDA generated by DCS adjusted for certain market adjustments. After adjusting for debt, Lakewood would be able to exercise their put option at a 15% discount to the implied equity value of the DCS subsidiary.</p> 850 7.92 107323 30000000 800000 3750000 3000000 0.20 0.0001 8.00 0.08 0.01 the Company will pay Lakewood a closing fee of $500,000 and reimbursement of out-of-pocket expenses not to exceed $200,000 in connection with closing the Dura Transaction. Additionally, the Company will pay Lakewood an aggregate annual management fee equal to 5% of Adjusted EBITDA which means for any period, consolidated earnings before interest, taxes, depreciation, and amortization adjusted to exclude extraordinary items, non-recurring items and other agreed upon items, with an annual cap of $1,000,000 ( the “Annual Management Fee”) with quarterly payments of $250,000 paid (January 1, April 1 and July 1) with final payment on October 1 to be approved by the audit committee of the Board of Directors equal to the difference between 5% Adjusted EBITDA and the $750,000 already paid. 500000 1000000 In addition, Lakewood will receive 15% of the equity of DCS within 10 days upon the closing of the DCS Transaction, that vests monthly over a two-year period which is currently estimated at approximately $4,500,000 based on the purchase price of $30,000,000. Lakewood also has the opportunity to receive additional liquidity for DCS by receiving a staggered (tranche-based) put option on its 15% of the DCS equity. No exercise of the put may be effected during the first two years after the closing of the Dura Transaction. After the end of year two, Lakewood has the option to sell up to 5% of the DCS equity in any twelve month period subject to a ninety day notice. false false false false false false false false false false false false Retroactively restated for a 1 for 40 reverse stock split on January 16, 2026 and a 1 for 30 reverse stock split on May, 11, 2026. Retroactively restated for a 1 for 40 reverse stock split on January 16, 2026 and a 1 for 30 reverse stock split on May, 11, 2026. Retroactively restated for a 1 for 40 reverse stock split on January 16, 2026 and a 1 for 30 reverse stock split on May, 11, 2026. International revenues are defined as revenues generated from sales to customers outside of the U. S. and Canada.